US20160367627A1 - Anti-tumor therapy - Google Patents
Anti-tumor therapy Download PDFInfo
- Publication number
- US20160367627A1 US20160367627A1 US14/901,929 US201414901929A US2016367627A1 US 20160367627 A1 US20160367627 A1 US 20160367627A1 US 201414901929 A US201414901929 A US 201414901929A US 2016367627 A1 US2016367627 A1 US 2016367627A1
- Authority
- US
- United States
- Prior art keywords
- cancer
- jak
- stat
- prostate cancer
- pathway
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002560 therapeutic procedure Methods 0.000 title description 30
- 230000000259 anti-tumor effect Effects 0.000 title description 2
- 230000004163 JAK-STAT signaling pathway Effects 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 27
- 206010060862 Prostate cancer Diseases 0.000 claims description 61
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 61
- 238000001959 radiotherapy Methods 0.000 claims description 49
- 239000002246 antineoplastic agent Substances 0.000 claims description 23
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 21
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims description 21
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims description 21
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 20
- 230000005855 radiation Effects 0.000 claims description 18
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 16
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 11
- 101000864662 Homo sapiens Probable ATP-dependent RNA helicase DHX58 Proteins 0.000 claims description 9
- 102100030090 Probable ATP-dependent RNA helicase DHX58 Human genes 0.000 claims description 9
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims description 6
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims description 6
- 238000002725 brachytherapy Methods 0.000 claims description 5
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 4
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 4
- 238000002710 external beam radiation therapy Methods 0.000 claims description 4
- 101001124792 Homo sapiens Proteasome subunit beta type-10 Proteins 0.000 claims description 3
- 102100029081 Proteasome subunit beta type-10 Human genes 0.000 claims description 3
- 229940124639 Selective inhibitor Drugs 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052792 caesium Inorganic materials 0.000 claims description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052741 iridium Inorganic materials 0.000 claims description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 153
- 201000011510 cancer Diseases 0.000 abstract description 83
- 239000003112 inhibitor Substances 0.000 abstract description 33
- 239000000203 mixture Substances 0.000 abstract description 13
- 210000004027 cell Anatomy 0.000 description 76
- 239000003814 drug Substances 0.000 description 70
- 108090000623 proteins and genes Proteins 0.000 description 67
- 229940079593 drug Drugs 0.000 description 50
- 102000015617 Janus Kinases Human genes 0.000 description 46
- 108010024121 Janus Kinases Proteins 0.000 description 46
- 238000011282 treatment Methods 0.000 description 46
- 230000000694 effects Effects 0.000 description 37
- 239000003826 tablet Substances 0.000 description 34
- 239000003795 chemical substances by application Substances 0.000 description 32
- 239000002552 dosage form Substances 0.000 description 30
- 239000007909 solid dosage form Substances 0.000 description 26
- 230000004083 survival effect Effects 0.000 description 23
- 239000004480 active ingredient Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 230000004654 survival pathway Effects 0.000 description 22
- 238000002512 chemotherapy Methods 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 239000007788 liquid Substances 0.000 description 21
- -1 S-4 Chemical compound 0.000 description 20
- 239000002775 capsule Substances 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 20
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 230000001629 suppression Effects 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 230000037361 pathway Effects 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 230000002280 anti-androgenic effect Effects 0.000 description 17
- 239000000051 antiandrogen Substances 0.000 description 17
- 238000013459 approach Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 16
- 102100032187 Androgen receptor Human genes 0.000 description 15
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 15
- 239000003098 androgen Substances 0.000 description 15
- 108010080146 androgen receptors Proteins 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 229930012538 Paclitaxel Natural products 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 229960001592 paclitaxel Drugs 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- 108010010803 Gelatin Proteins 0.000 description 12
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 12
- 229960003668 docetaxel Drugs 0.000 description 12
- 239000008273 gelatin Substances 0.000 description 12
- 229920000159 gelatin Polymers 0.000 description 12
- 235000019322 gelatine Nutrition 0.000 description 12
- 235000011852 gelatine desserts Nutrition 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 229940127089 cytotoxic agent Drugs 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 10
- 229940123237 Taxane Drugs 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- 230000005865 ionizing radiation Effects 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 230000003111 delayed effect Effects 0.000 description 8
- 238000013265 extended release Methods 0.000 description 8
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 7
- 229960001573 cabazitaxel Drugs 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 208000014829 head and neck neoplasm Diseases 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000001665 lethal effect Effects 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- YVXVTLGIDOACBJ-SFHVURJKSA-N (2S)-3-(4-acetamidophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC[C@](C)(O)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YVXVTLGIDOACBJ-SFHVURJKSA-N 0.000 description 6
- JNGVJMBLXIUVRD-SFHVURJKSA-N (2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)OC1=CC=C(C#N)C=C1 JNGVJMBLXIUVRD-SFHVURJKSA-N 0.000 description 6
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 6
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 6
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 6
- 102100023978 Signal transducer and activator of transcription 2 Human genes 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 6
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 239000005414 inactive ingredient Substances 0.000 description 6
- 231100000518 lethal Toxicity 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 6
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 6
- 239000003380 propellant Substances 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 5
- 102000000887 Transcription factor STAT Human genes 0.000 description 5
- 108050007918 Transcription factor STAT Proteins 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 4
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 4
- KEJORAMIZFOODM-PWSUYJOCSA-N 2-chloro-4-[(7r,7as)-7-hydroxy-1,3-dioxotetrahydro-1h-pyrrolo[1,2-c]imidazol-2(3h)-yl]-3-methylbenzonitrile Chemical compound CC1=C(Cl)C(C#N)=CC=C1N1C(=O)N2CC[C@@H](O)[C@H]2C1=O KEJORAMIZFOODM-PWSUYJOCSA-N 0.000 description 4
- JPQFGMYHKSKKGW-UHFFFAOYSA-N 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S JPQFGMYHKSKKGW-UHFFFAOYSA-N 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 4
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- HYNANJUKEMCYEQ-HIGHGGLBSA-N N-[(3aR,4R,5R,7R,7aS)-2-[4-cyano-3-(trifluoromethyl)phenyl]-4,7-dimethyl-1,3-dioxo-3a,5,6,7a-tetrahydro-octahydro-1H-4,7-epoxyisoindol-5-yl]ethanesulfonamide Chemical compound O=C([C@H]1[C@@H](C2=O)[C@@]3(C)O[C@]1(C)C[C@H]3NS(=O)(=O)CC)N2C1=CC=C(C#N)C(C(F)(F)F)=C1 HYNANJUKEMCYEQ-HIGHGGLBSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 4
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960000640 dactinomycin Drugs 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229960002074 flutamide Drugs 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- OMXGOGXEWUCLFI-UHFFFAOYSA-N lgd-3303 Chemical compound N1C(=O)C=C(Cl)C2=C1C=CC1=C2C(C)=C(CC)N1CC(F)(F)F OMXGOGXEWUCLFI-UHFFFAOYSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 4
- 229960001428 mercaptopurine Drugs 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229960003171 plicamycin Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 4
- 229940063683 taxotere Drugs 0.000 description 4
- 230000004797 therapeutic response Effects 0.000 description 4
- 229960003087 tioguanine Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 3
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000012829 chemotherapy agent Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229940025735 jevtana Drugs 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000003439 radiotherapeutic effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229960000215 ruxolitinib Drugs 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- SSFVOEAXHZGTRJ-KRWDZBQOSA-N (2s)-3-(4-chloro-3-fluorophenoxy)-n-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)OC1=CC=C(Cl)C(F)=C1 SSFVOEAXHZGTRJ-KRWDZBQOSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 description 2
- 102100035473 2'-5'-oligoadenylate synthase-like protein Human genes 0.000 description 2
- YNYAUBNZRZVNLX-KBPBESRZSA-N 2-[(2s,4s)-4-(dimethylamino)-6-nitro-1,2,3,4-tetrahydroquinolin-2-yl]-2-methylpropan-1-ol Chemical compound C1=C([N+]([O-])=O)C=C2[C@@H](N(C)C)C[C@@H](C(C)(C)CO)NC2=C1 YNYAUBNZRZVNLX-KBPBESRZSA-N 0.000 description 2
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 description 2
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- SQSZANZGUXWJEA-UHFFFAOYSA-N Gandotinib Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 description 2
- 101000597360 Homo sapiens 2'-5'-oligoadenylate synthase-like protein Proteins 0.000 description 2
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 2
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 description 2
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- 101000952073 Homo sapiens Probable ATP-dependent RNA helicase DDX60-like Proteins 0.000 description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 description 2
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 2
- 101150009057 JAK2 gene Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- UUQHKWMIDYRWHH-UHFFFAOYSA-N Methyl beta-orcinolcarboxylate Chemical compound COC(=O)C1=C(C)C=C(O)C(C)=C1O UUQHKWMIDYRWHH-UHFFFAOYSA-N 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 2
- IPRJXAGUEGOFGG-UHFFFAOYSA-N N-butylbenzenesulfonamide Chemical compound CCCCNS(=O)(=O)C1=CC=CC=C1 IPRJXAGUEGOFGG-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102100037440 Probable ATP-dependent RNA helicase DDX60-like Human genes 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229940083324 Selective androgen receptor modulator Drugs 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241001116500 Taxus Species 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 102100031013 Transgelin Human genes 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001780 adrenocortical effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical class C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 2
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940097647 casodex Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003034 chemosensitisation Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 125000000567 diterpene group Chemical group 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229950001115 enobosarm Drugs 0.000 description 2
- 229960004671 enzalutamide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002721 intensity-modulated radiation therapy Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007942 layered tablet Substances 0.000 description 2
- OPSIVAKKLQRWKC-VXGBXAGGSA-N lgd-4033 Chemical compound FC(F)(F)[C@H](O)[C@H]1CCCN1C1=CC=C(C#N)C(C(F)(F)F)=C1 OPSIVAKKLQRWKC-VXGBXAGGSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000001455 metallic ions Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 229940099637 nilandron Drugs 0.000 description 2
- 229960002653 nilutamide Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003956 nonsteroidal anti androgen Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 229950011410 pacritinib Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000000637 radiosensitizating effect Effects 0.000 description 2
- 229960005562 radium-223 Drugs 0.000 description 2
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000849 selective androgen receptor modulator Substances 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000006211 transdermal dosage form Substances 0.000 description 2
- 150000004654 triazenes Chemical class 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 229920003176 water-insoluble polymer Polymers 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 229940085728 xtandi Drugs 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 description 1
- GXAFMKJFWWBYNW-OWHBQTKESA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC2CC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GXAFMKJFWWBYNW-OWHBQTKESA-N 0.000 description 1
- CTBYOENFSJTSBT-UHFFFAOYSA-N 2-oxobutanedioic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.OC(=O)CC(=O)C(O)=O CTBYOENFSJTSBT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 238000002729 3-dimensional conformal radiation therapy Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102100028162 ATP-binding cassette sub-family C member 3 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101100107070 Arabidopsis thaliana ZAT2 gene Proteins 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000044650 Deleted in Azoospermia 1 Human genes 0.000 description 1
- 108700042671 Deleted in Azoospermia 1 Proteins 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100039621 Epithelial-stromal interaction protein 1 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 102100028541 Guanylate-binding protein 2 Human genes 0.000 description 1
- 102100029076 Histamine N-methyltransferase Human genes 0.000 description 1
- 101000986633 Homo sapiens ATP-binding cassette sub-family C member 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101100498454 Homo sapiens DAZ1 gene Proteins 0.000 description 1
- 101000814134 Homo sapiens Epithelial-stromal interaction protein 1 Proteins 0.000 description 1
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 description 1
- 101001058858 Homo sapiens Guanylate-binding protein 2 Proteins 0.000 description 1
- 101000988655 Homo sapiens Histamine N-methyltransferase Proteins 0.000 description 1
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 1
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 description 1
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 1
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 description 1
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 description 1
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 description 1
- 101001082058 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 description 1
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 description 1
- 101001034844 Homo sapiens Interferon-induced transmembrane protein 1 Proteins 0.000 description 1
- 101001034842 Homo sapiens Interferon-induced transmembrane protein 2 Proteins 0.000 description 1
- 101001034846 Homo sapiens Interferon-induced transmembrane protein 3 Proteins 0.000 description 1
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 description 1
- 101000979565 Homo sapiens Protein NLRC5 Proteins 0.000 description 1
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 description 1
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 description 1
- 101000879840 Homo sapiens Serglycin Proteins 0.000 description 1
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
- 101000680652 Homo sapiens Tripartite motif-containing protein 14 Proteins 0.000 description 1
- 101000942626 Homo sapiens UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
- 101000662026 Homo sapiens Ubiquitin-like modifier-activating enzyme 7 Proteins 0.000 description 1
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 101000761740 Homo sapiens Ubiquitin/ISG15-conjugating enzyme E2 L6 Proteins 0.000 description 1
- 101000639143 Homo sapiens Vesicle-associated membrane protein 5 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 230000006133 ISGylation Effects 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 description 1
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 1
- 102100029607 Interferon-induced protein 44 Human genes 0.000 description 1
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 description 1
- 102100027303 Interferon-induced protein with tetratricopeptide repeats 2 Human genes 0.000 description 1
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 description 1
- 102100040021 Interferon-induced transmembrane protein 1 Human genes 0.000 description 1
- 102100040020 Interferon-induced transmembrane protein 2 Human genes 0.000 description 1
- 102100040035 Interferon-induced transmembrane protein 3 Human genes 0.000 description 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000018671 Lymphocyte Antigen 96 Human genes 0.000 description 1
- 108010066789 Lymphocyte Antigen 96 Proteins 0.000 description 1
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108700006140 Myeloid Cell Leukemia Sequence 1 Proteins 0.000 description 1
- 102000046234 Myeloid Cell Leukemia Sequence 1 Human genes 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 1
- 102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100023432 Protein NLRC5 Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 description 1
- HCWPIIXVSYCSAN-IGMARMGPSA-N Radium-226 Chemical compound [226Ra] HCWPIIXVSYCSAN-IGMARMGPSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100037344 Serglycin Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102100022350 Tripartite motif-containing protein 14 Human genes 0.000 description 1
- 102100032947 UMP-CMP kinase 2, mitochondrial Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100037938 Ubiquitin-like modifier-activating enzyme 7 Human genes 0.000 description 1
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 1
- 102100024843 Ubiquitin/ISG15-conjugating enzyme E2 L6 Human genes 0.000 description 1
- 102100031484 Vesicle-associated membrane protein 5 Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004642 autophagic pathway Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 230000005025 clonogenic survival Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000009110 definitive therapy Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 230000011542 interferon-beta production Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 108010076401 isopeptidase Proteins 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229940045773 jakafi Drugs 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229950001845 lestaurtinib Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 101150094281 mcl1 gene Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000012379 oncolytic virotherapy Methods 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-OIOBTWANSA-N palladium-103 Chemical compound [103Pd] KDLHZDBZIXYQEI-OIOBTWANSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 238000002727 particle therapy Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 239000012132 radioimmunoprecipitation assay buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 201000011453 reproductive organ cancer Diseases 0.000 description 1
- 208000028466 reproductive system neoplasm Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- JFMWPOCYMYGEDM-XFULWGLBSA-N ruxolitinib phosphate Chemical compound OP(O)(O)=O.C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 JFMWPOCYMYGEDM-XFULWGLBSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to the identification and control of the JAK/STAT pathway for treatment of cancers, including chemoresistant and/or radioresistant cancers.
- Prostate cancer is the second leading cause of cancer-related death in men with more than 28,000 Americans dying annually. In order for a cancer to be “successful” in the host it must survive typical oncogenic processes, as well as treatment regimens including iatrogenic insults, including androgen ablation, the more recently approved potent androgen receptor (AR) targeted agents, and often radiotherapy and taxane-based chemotherapy as well.
- a locally advanced prostate cancer and metastatic castrate resistant prostate cancer (mCRPC) also regularly develop resistance to the cytotohic host microenviroment and genotoxic anti-tumor therapy.
- prostate cancer tends to metastasize to bone, leading to significant morbidity and functional limitations prior to its lethal effects.
- a cancer for which a number of localized and systemic therapies are available and in fact is an example of the success of molecular targeted oncology treatment.
- AR androgen receptor
- DNA and DNA-repair targeted therapies have also been shown to be modestly effective in improving survival or ameliorating symptoms in this disease including the tubule targeted agents docetaxel and cabazitaxel, and radiotherapy with alpha (Ra 233 ), beta (Sr 89 ), and gamma (photon) particles.
- JAK targeted therapy is being investigated for the treatment of myeloproliferative diseases.
- Ruxolitinib (INCB018424, trade names Jakafi® and Jakavi®, by Incyte Pharmaceuticals and Novartis, CAS 941678-49-5) was developed for the treatment of intermediate or high-risk myelofibrosis, a type of bone marrow cancer.
- JAK/STAT pathway While the importance of the JAK/STAT pathway, in general, for cancers continues to be investigated, the role it plays in tumors remains undefined. Consequently, there is an urgent and definite need to identify therapies that may potentially have a role in tumor development associated with the JAK/STAT pathway. Such therapies may provide new treatments for JAK/STAT-related cancers, and/or therapies targeted to the sensitization of cancers for chemotherapies and/or radiotherapies. Targeting JAK/STAT could thus inhibit a fundamental property of the malignant phenotype and open the door to multiple therapies, including combination therapy.
- a first aspect of the invention provides a method of treating a subject with a chemoresistant or radioresistant prostate cancer.
- the method comprises administering a therapeutically effective amount of an inhibitor of a JAK/STAT pathway to the subject.
- the cancer is associated with activation of a JAK/STAT-related pathway.
- JAK includes a JAK1, a JAK2, a JAK3 or a Tyk2 kinase
- the STAT includes a STAT1, a STAT2, a STAT3, a STAT4, a STAT5, or a STAT6 transcriptional factor
- the inhibitor of the JAK/STAT pathway inhibits at least one of a JAK, and consequently at least one of a STAT.
- the prostate cancer has an amplified level of MCL1 or LGP2 (DHX58) or immunoproteasome subunits PSMB8, 9, 10 expression as compared to a normal control cell.
- FIG. 1 shows the results of a gene profiling experiment using Affymetrix microarrays on PC3 prostate cancer mouse xenografts following irradiation
- FIG. 2 shows the effect of JAK2 inhibitor SAR302503 in prostate cancer cell lines CWRR1 and CW22Rv1 treated with gamma radiation;
- FIG. 3 shows the effect of JAK2 inhibitor SAR302503 in prostate cancer xenografts treated with gamma radiation
- FIG. 4 (presented as FIGS. 4A and 4B ) shows that expression of MCL1, USP18, DHX58 (LGP2) and PSMB8 and 10 confers post-radiation survival of prostate cancer cell lines CWRR1 and CW22Rv1.
- a JAK/STAT dependent cancer may include any solid tumor, including lung, prostate, head and neck, breast and colorectal cancer, melanomas and gliomas, and the like. While the present disclosure may be embodied in different forms, several specific embodiments are discussed herein with the understanding that the present disclosure is to be considered only an exemplification and is not intended to limit the invention to the illustrated embodiments.
- JAK kinases are associated with a variety of cytokine and growth factor receptors, and signal through several down-stream STAT homologs; however, the specific signaling pathways are quite complex and difficult to predict from disease to disease.
- receptors that are known to operate predominantly through JAK-dependent activation of a specific STAT protein, such as STAT1 through IFN- ⁇ receptor activation or STAT3 through IL6/IL6R receptor gp130 activation can cross-activate alternative STATS. This may occur through JAK cross-phosphorylation as has been demonstrated in the context of IFN- ⁇ signaling in which cross phosphorylation of JAK1 and JAK2 has been demonstrated. Additional complexities of the JAK/STAT signaling pathway are introduced by the extensive interactions between different STATS.
- STAT1 and STAT3 can form heterodimers both in the phosphorylated and non-phosphorylated forms. Further, STAT1 and STAT3 can both bind to the same promoter sequences of the same genes (including oncogenes MUC1 and MCL1). Therefore, although the JAK/STAT signaling pathway may have been previously described in other diseases including some specific cancers, the correlation to other diseases and cancers and its complex interactions cannot be readily ascertained by reference only to this other previously described disease or cancer.
- JAK and STAT components of this signaling pathway are complex.
- the development of small molecules and peptide inhibitors of individual JAK kinases and STAT proteins is rather rapid. Therefore, it is important to evaluate functional consequences of the inhibition of individual members of this cascade in a target cancer for which the effects have not been determined such as in prostate cancer.
- the specific JAK and STAT proteins, as well as the relevant upstream and downstream mediators appear to differ across the cancer spectrum.
- the majority of investigations into the biology and role of the JAK/STAT pathway do not necessarily consider this subtlety. This reality challenges the contemporary notion that these survival pathways are homogeneous in various cancers.
- JAK2 via knockdown
- vs. castrate low
- vs. castrate-resistant-like androgen levels no androgens present
- Martinez H., et al. Androgen-Sensitive Microsomal Signaling Networks Couples to the Proliferation and Differentiation of Human Prostate Cancer Cells, Genes & Cancer 2(10) 956-978.
- the dual JAK1/JAK2 inhibitor ruxtolitinib failed to show efficacy in a Phase II clinical trial with androgen-independent prostate cancer.
- this dual JAK1/JAK2 inhibitor did not work in patients with androgen-independent prostate cancer, it would not be readily expected by one skilled in the art that a JAK2 inhibitor alone would work either.
- specific inhibition of JAK2 either alone or in combination with one or more anticancer agents, such as radiotherapy, for example, will be effective in treating prostate cancer in a subject.
- JAK/STAT pathway is not being investigated in prostate cancer as a potentially targetable survival pathway for which inhibition, and possibly in conjunction with other lethal insults such as combination therapy may be clinically pragmatic.
- a number of mCRPC treatments targeting various androgen receptor and non-androgen receptor pathways are in development, but are expected to be limited by the fundamental activation of specific survival pathways in this disease.
- Targeting JAK/STAT could thus inhibit a fundamental property of the malignant phenotype and open the door to multiple therapies including, for example, combination therapy.
- mCRPC mCRPC
- a “successful” cancer in a subject has survived a myriad of insults that would be expected to be lethal to most cells.
- Applicants now show that certain cellular survival pathways are upregulated and highly active in mCRPC. It is expected that such cells would be resistant to further lethal insults (for example, chemotherapy and/or radiotherapy) and successful therapy may employ the addition of a survival pathway inhibitor.
- the survival pathway in such cancers including those that are chemoresistant and/or radioresistant, is believed to be the JAK/STAT pathway, which may include, for example, the JAK2/STAT1-STAT3 signaling members.
- the anti-apoptotic protein MCL1 is a downstream mediator of this survival pathway. It is further expected that the JAK/STAT pathway maintains cancer cell survival status and is, therefore, a viable therapeutic target.
- One approach is to determine JAK/STAT pathway survival mechanisms in a particular cancer. By utilizing a combination of sh/siRNA and chemical approaches with JAK2 specific and broader JAK1/2 inhibitors in genetically related cancer cell lines, for example, CWRR1 (resistant to JAK2 inhibition) and CW22RV1 (sensitive to JAK2 inhibition) in prostate cancer, the relative contributions of JAK1 and JAK2 can be determined as well as the relative contribution of STAT1 versus STAT3 in mediating survival. Further, the role of MCL1 as an effector of the JAK/STAT survival pathway in the particular cancer can also be evaluated.
- Applicants have now shown that in hormone resistant prostate cancer cells, sensitive to JAK inhibitors, JAK2 inhibitors alone can suppress tumor growth and in combination with ionizing radiation lead to significant suppression of tumor growth ( FIGS. 1 and 2 ). Based on this observation, a JAK2 inhibitor can be used as primary therapy in patients with hormone resistant prostate cancer (localized) and/or treatment of hormone refractory metastatic prostate cancer for cure or palliation in combination with radio isotopes such as summerium and radium 223, which are employed in metastatic hormone refractory cancer.
- JAK2 inhibition will enhance classic cytotoxic therapy, such as the standard taxanes.
- Taxanes are produced by the plants of the genus Taxus and are classified as diterpenes and widely used as chemotherapy agents including, for example, paclitaxel (Taxol®, Bristol-Meyers Squibb, CAS 33069-62-4) or docetaxel (Taxotere®, Sanofi-Aventis, CAS 114977-28-5). It is also contemplated that combinations of semi-synthetic derivatives of a natural taxoid and a JAK2 inhibitor will also enhance cytotoxic therapy.
- JAK2 inhibitors include, for example, CYT387 (YM BioSciences Inc., CAS 1056634-68-4), SB1518 [pacritinib, S*BIO Pte Ltd.
- JAK2 inhibitor therapy for the treatment of cancer contemplated herein, include radiotherapy, and other cancer specific agents, such as an androgen receptor inhibitor or mediator.
- Illustrative androgen receptor inhibitors include, for example, a steroidal antiandrogen (for example, cyperterone, CAS 2098-66-0); a non-steroidal antiandrogen (for example, flutamide, Eulexin®, Schering-Plough, CAS 13311-84-7); nilutamide (Nilandron®, CAS 63612-50-0); enzalutamide (Xtandi®, Medivation, CAS 915087-33-1); bicalutamide (Casodex®, AstraZeneca, CAS 90357-06-5); a peptide antiandrogen; a small molecule antiandrogen (for example, RU58642 (Roussel-Uclaf SA, CAS 143782-63-2); LG120907 and LG105 (Ligand Pharmaceuticals); RD162 (Medivation, CAS 915087-27-3); BMS-641988 (Bristol-Meyers
- cancer specific agents or chemotherapeutic agents that may be used in combination with JAK inhibitor therapy include, for example: alkylating agents such as nitrogen mustards such as mechlorethamine (HN 2 ), cyclophosphamide, ifosfamide, melphalan (L-sarcolysin) and chlorambucil; ethylenimines and methylmelamines such as hexamethylmelamine, thiotepa; alkyl sulphonates such as busulfan; nitrosoureas such as carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU) and streptozocin (streptozotocin); and triazenes such as decarbazine (DTIC; dimethyltriazenoimidazole-carboxamide); antimetabolites including folic acid analogues such as methotrexate (amethopterin); pyrimidine analogues such as fluorouracil (5-
- activation of the JAK/STAT pathway is a survival pathway for a proportion of cancers surviving in a subject and that targeting this pathway will result in a toxic insult to the cancer, leading to, for example, inhibiting the growth or proliferation of the cancer, inducing the killing of the cancer, and/or inhibiting or reversing the development or progression of the cancer in a subject.
- novel therapies can be developed for this lethal and burdensome disease, and may also provide therapeutic insight into adaptive mechanisms that can be ascertained as operative in malignancies such as tumors and cancer: a) dissect the components of the JAK/STAT pathway that are most relevant to the cancer survival phenotype, b) develop biomarkers for identifying the cancers with this pathway activated and which are thus susceptible to its targeting, c) develop the clinical science of introducing JAK inhibitors to the treatment of the cancer in a subject, and d) develop inhibitor(s) of the JAK/STAT pathway, including selective inhibitors to the most relevant components of the JAK/STAT pathway responsible for the survival phenotype.
- JAK/STAT survival pathway signaling are context and disease specific.
- this signature is comprised of genes activated by JAK1/JAK2/STAT1/STAT3 signaling.
- This activated JAK/STAT pathways are common in multiple clinical and preclinical tumor models, and have been linked to poor prognosis.
- anti-sense inhibition of STAT3 has been suggested to enhance apoptosis in prostate cancer cell lines.
- Applicants' results show that the components mediating the survival pathway in prostate cancer are JAK1, JAK2, STAT1 and STAT3.
- Applicants' approach includes pharmacological and h/siRNA-based approaches combined with growth/survival assays, biochemical analysis and whole-genome expressional profiling to estimate the relative contribution of JAK1, JAK2, STAT1 and STAT3 on growth and radio/chemoresistance of prostate cancer cells.
- MCL1 is a mediator of the JAK/STAT dependent survival phenotype and provides not only mechanistic insight, but an additional therapeutic target to prostate cancer.
- JAK/STAT signaling is needed for maintaining cancer cell survival in a subset of cancers, including, for example, late stage castrate resistant prostate cancers, particularly in the context of additional toxic insults, and is therefore a therapeutic target.
- mCRPC for example, a multi-prong, interdisciplinary, and highly interactive approach was taken with three basic approaches. The first approach identified and elucidated the specifics of the JAK/STAT pathway relevant for the survival phenotype in mCRPC utilizing a combination of genetic and chemical approaches. The second approach develops the clinical science necessary for introducing JAK inhibitors into the therapeutic armamentarium under the hypothesis that effective targeting may include combination strategies.
- STAT3 on JAK/STAT-dependent tumor survival and 2) to validate MCL1 as a down-stream mediator of JAK/STAT-dependent survival pathways and as a potential additional target for radio/chemosensitization of hormone-resistant prostate cancer; and within the second approach there were three subaims: 1) to conduct in vivo xenograft studies of SAR302503 in combination with various standard prostate cancer treatments, and 2) to conduct a human phase 1 clinical trial of SAR302503 and cabazitaxel in patients with castrate resistant prostate cancer.
- subject refers to any organism classified as a mammal, including mice, rats, guinea pigs, rabbits, dogs, cats, cows, horses, monkeys, and other mammals. In one preferred embodiment, the subjects are humans.
- cancer refers to a class of diseases of mammals characterized by uncontrolled cellular growth.
- cancer is used interchangeably with the terms “tumor,” “solid tumor,” “malignancy,” “hyperproliferation” and “neoplasm.”
- Cancer includes all types of hyperproliferative growth, hyperplasic growth, neoplastic growth, cancerous growth or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness.
- Illustrative examples include, lung, prostate, head and neck, breast and colorectal cancer, melanomas and gliomas (such as a high grade glioma, including glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adult humans).
- melanomas and gliomas such as a high grade glioma, including glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adult humans.
- GBM glioblastoma multiforme
- solid tumor includes, for example, lung cancer, head and neck cancer, brain cancer, oral cancer, colorectal cancer, breast cancer, prostate cancer, pancreatic cancer, and liver cancer.
- Other types of solid tumors are named for the particular cells that form them, for example, sarcomas formed from connective tissue cells (for example, bone cartilage, fat), carcinomas formed from epithelial tissue cells (for example, breast, colon, pancreas) and lymphomas formed from lymphatic tissue cells (for example, lymph nodes, spleen, thymus). Treatment of all types of solid tumors regardless of naming convention is within the scope of this invention.
- JAK Janus Kinase refers to a family of intracellular, nonreceptor tyrosine kinases. JAK may include four family members, Janus 1 (JAK1), Janus 2 (JAK2), Janus 3 (JAK3), and Tyrosine kinase 2 (Tyk2).
- STAT Signal Transducer and Activator of Transcription plays a role in regulating cell growth, survival and differentiation and the family includes STAT1, STAT2, STAT 3, STAT4, STAT5 (STAT5a and STAT5b), and STATE.
- JK/STAT pathway inhibitor refers to an inhibitor that provides inhibition of the pathway to an extent that can be measured by conventional biochemical techniques.
- JAK inhibitor will be therapeutically useful in a subject with a cancer having an activated JAK.
- the activity of JAK and its family members can be measured directly by kinase assay, or indirectly by staining with commercially available antibodies (including, for example, antibody for total Jak2 sc-294, and antibody for activated (phosphorylated) Jak2 c-21870, Santa Cruz Biotechnology, CA), as is well known to a person skilled in the art.
- JAK inhibitors may not work in a subject with a cancer that express little or no levels of MCL1.
- a typical subject is one with cancer that expresses elevated or high levels of MCL1 as compared to a normal non-disease state subject.
- transcriptional data see Oncomine: https://www.oncomine.org/resource/main.html
- expressional levels of MCL1 mRNA are increased in prostate carcinomas relative to normal prostate tissues at 20-30% in average (see Taylor B S et al., Cancer Cell, 2010 , Integrative genomic profiling of human prostate cancer . Cancer Cell.
- the JAK inhibitor may be, for example, a molecule that binds to the active or inactive conformation of the kinase ATP pocket or a non-ATP competitive kinase inhibitor, and can be a small molecule, a polynucleotide, or encoded by a polynucleotide, for example.
- Polynucleotides may be administered by any effective method known in the art, for example, parenterally (e.g., intravenously, subcutaneously, intramuscularly) or by oral, nasal or other means that permit the oligonucleotides to access and circulate in the subject's bloodstream.
- Polynucleotides administered systemically may be given in addition to locally administered polynucleotides, but also have utility in the absence of local administration. A dosage in the range of from about 0.1 to about 10 grams per administration to an adult human will likely be effective for this purpose.
- the polynucleotide may also be administered as a suitable genetic construct or as nanoparticle (as is described in Costa P M et al., Mol Ther Nucleic Acids. 2013 June 18; 2:e100) and delivered to the subject where it is expressed.
- the polynucleotide in the genetic construct is operatively linked to a promoter that can express the compound in the cell.
- the genetic constructs can be prepared using methods well known in the art, for example, Gil M, Seshadri M, Komorowski M P, Abrams S I, Kozbor D., Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases, Proc Natl Acad Sci USA. 2013 April 2; 110(14):E1291-300.
- the present disclosure also includes the use of an inhibitor of JAK or polynucleotide which encodes an inhibitor of JAK in the preparation of a medicament for the treatment of cancer, including prostate cancer, and in a subject, who may also be administered a further anti-cancer agent.
- the subject may have been administered the anti-cancer agent previously, or is administered the anti-cancer agent simultaneously with the medicament, or is administered the anti-cancer agent after the medicament.
- selective JAK/STAT pathway inhibitor refers to an inhibitor that inhibits a particular member of the JAK or STAT family a greater extent than that of another member of the family.
- a selective JAK inhibitor may include: 1) an inhibitor that selectively inhibits JAK1 but not JAK2, JAK3, or Tyk2; or 2) an inhibitor that selectively inhibits JAK2 but not JAK1, JAK3, or Tyk2.
- a selective STAT inhibitor may include, for example: 1) an inhibitor that selectively inhibits STAT 1, but not STAT2, STAT 3, STAT4, STAT5 (STAT5a and STAT5b), and STAT6; or 2) an inhibitor that selectively inhibits STAT 2, but not STAT1, STAT 3, STAT4, STAT5 (STAT5a and STAT5b), and STAT6.
- Selective inhibition refers to inhibition of the particular family member that is about 2-fold to about 10-fold greater than that of the other family members (that is based on differences in the constants of inhibition).
- Suppression of a gene refers to the absence of expression of a gene or a decrease in expression of a gene as compared to the activity of an untreated gene. Suppression of a gene may be determined by detecting the presence or absence of expression of a gene or by measuring a decrease of expression of a gene by any means known in the art including, for example, detecting a decrease in the level of the final gene product, such as a protein, or detecting a decreased level of a precursor, such as mRNA, from which gene expression levels may be inferred when compared to normal gene activity, such as a negative (untreated) control. Any molecular biological assay to detect mRNA or an immunoassay to detect a protein known in the art can be used.
- a molecular biological assay may include, for example, polymerase chain reaction (PCR), Northern blot, Dot blot, or an analysis method with microarray or macroarray.
- An immunological assay includes, for example, ELISA (enzyme-linked immunosorbent assay) with a microtiter plate, radioimmunoassay (RIA), a fluorescence antibody technique, Western blotting, or an immune structure dyeing method. Suppression of a gene may also be inferred biologically in vivo, in situ, and/or in vitro, by the suppression of growth or proliferation of a tumor or cancer cell, cell death of a tumor or cancer cell, and/or the sensitization of a tumor or cancer cell to chemotherapy and/or radiotherapy.
- a therapeutically effective amount of gene suppression in a subject results in the suppression of growth or proliferation of a tumor or cancer cell, cell death of the tumor or cancer cell, and/or the sensitization of the tumor or cancer cell to chemotherapy and/or radiotherapy.
- the amount of gene suppression to achieve a therapeutically effective amount of gene suppression may be determined by a trained professional skilled in the area on a case-by-case basis.
- a therapeutically effective amount of gene suppression may include, for example, less than or equal to about 95% of normal gene activity, or less than or equal to about 90% of normal gene activity, or less than or equal to about 85% of normal gene activity, or less than or equal to about 80% of normal gene activity, or less than or equal to about 75% of normal gene activity, or less than or equal to about 65% of normal gene activity, or less than or equal to about 50% of normal gene activity, or less than or equal to about 35% of normal gene activity, or less than or equal to about 25% of normal gene activity, or less than or equal to about 15% of normal gene activity, or less than or equal to about 10% of normal gene activity, or less than or equal to about 7.5% of normal gene activity, or less than or equal to about 5% of normal gene activity, or less than or equal to about 2.5% of normal gene activity, or less than or equal to about 1% of normal gene activity, or less than or equal to about 0% of normal gene activity.
- Suppression of identified genes individually or in combination with ionizing radiation and/or any chemotherapeutic agents may improve the outcome of patients treated with the ionizing radiation or any chemotherapy agent or any treatment designed to improve outcome of the cancer patients (like JAK1/JAK2 inhibitors) if such treatment is combined with the suppression of any of these genes or their combination.
- Radiotherapy is based on ionizing radiation delivered to a target area that results in death of reproductive tumor cells.
- Some examples of radiotherapy include the radiation of cesium, palladium, iridium, iodine, or cobalt radiotherapy which is usually delivered as ionizing radiation from a linear accelerator or an isotopic source such as a cobalt source.
- linear accelerators are Cyberkine and Tomotherapy.
- Particle radiotherapy from cyclotrons such as Protons or Carbon nuclei may be employed.
- radioisotopes delivered systemically such as p32 or radium 223 may be used.
- the external radiotherapy may be systemic radiation in the form of sterotacktic radiotherapy total nodal radiotherapy or whole body radiotherapy but is more likely focused to a particular site, such as the location of the tumor or the solid cancer tissues (for example, abdomen, lung, liver, lymph nodes, head, etc.).
- the radiation dosage regimen is generally defined in terms of Gray or Sieverts time and fractionation, and must be carefully defined by the radiation oncologist.
- the amount of radiation a subject receives will depend on various considerations. The two important considerations are the location of the tumor in relation to other critical structures or organs of the body, and the extent to which the tumor has spread.
- One illustrative course of treatment for a subject undergoing radiation therapy is a treatment schedule over a 5 to 8 week period, with a total dose of 50 to 80 Gray (Gy) administered to the subject in a single daily fraction of 1.8 to 2.0 Gy, 5 days a week.
- Gy is an abbreviation for Gray and refers to 100 rad of dose.
- Radiotherapy can also include implanting radioactive seeds inside or next to an site designated for radiotherapy and is termed brachytherapy (or internal radiotherapy, endocurietherapy or sealed source therapy).
- brachytherapy or internal radiotherapy, endocurietherapy or sealed source therapy
- permanent brachytherapy radioactive (iodine-125 or palladium-103) seeds are implanted into the prostate gland using an ultrasound for guidance.
- about 40 to 100 seeds are implanted and the number and placement are generally determined by a computer-generated treatment plan known in the art specific for each subject.
- Temporary brachytherapy uses a hollow sources placed into the prostate gland that is filled with radioactive material (iridium-192) for about 5 to about 15 minutes, for example. Following treatment, the needle and radioactive material are removed. This procedure is repeated two to three times over a course of several days.
- Radiotherapy can also include radiation delivered by external beam radiation therapy (EBRT), including, for example, a linear accelerator (a type of high-powered X-ray machine that produces very powerful photons that penetrate deep into the body); proton beam therapy where photons are derived from a radioactive source such as iridium-192, caesium-137, radium-226 (no longer used clinically), or colbalt-60; Hadron therapy; multi-leaf collimator (MLC); and intensity modulated radiation therapy (IMRT).
- EBRT external beam radiation therapy
- a linear accelerator a type of high-powered X-ray machine that produces very powerful photons that penetrate deep into the body
- proton beam therapy where photons are derived from a radioactive source such as iridium-192, caesium-137, radium-226 (no longer used clinically), or colbalt-60
- Hadron therapy multi-leaf collimator (MLC); and intensity modulated radiation therapy (IMRT).
- EBRT there are several ways to deliver EBRT, including, for example, three-dimensional conformal radiation therapy where the beam intensity of each beam is determined by the shape of the tumor.
- Illustrative dosages used for photon based radiation is measured in Gy, and in an otherwise healthy subject (that is, little or no other disease states present such as high blood pressure, infection, diabetes, etc.) for a solid epithelial tumor ranges from about 60 to about 80 Gy, and for a lymphoma ranges from about 20 to about 40 Gy.
- Illustrative preventative (adjuvant) doses are typically given at about 45 to about 60 Gy in about 1.8 to about 2 Gy fractions for breast, head, and neck cancers.
- Radiation therapy has also been combined temporally with chemotherapy to improve the outcome of treatment.
- various terms to describe the temporal relationship of administering radiation therapy and chemotherapy and the following examples are illustrative treatment regimens and are generally known by those skilled in the art and are provided for illustration only and are not intended to limit the use of other combinations.
- “Sequential” radiation therapy and chemotherapy refers to the administration of chemotherapy and radiation therapy separately in time in order to allow the separate administration of either chemotherapy or radiation therapy.
- Consitant radiation therapy and chemotherapy refers to the administration of chemotherapy and radiation therapy on the same day.
- alternating radiation therapy and chemotherapy refers to the administration of radiation therapy on the days in which chemotherapy would not have been administered if it was given alone.
- radiotherapy can be determined by a radiation oncologist skilled in the art and can be based on, for example, whether the subject is receiving chemotherapy, if the radiation is given before or after surgery, the type and/or stage of cancer, the location of the tumor, and the age, weight and general health of the subject.
- DHX58 also known as LGP2
- IFITM1 and OASL are known anti-viral proteins.
- USP18 and HERC5 are enzymes involved in protein ISGylation/de-ISGylation, known to protect proteins from ubiquitin-dependent degradation in proteosome complex, while PSMB9 and PSMB10 are proteasome subunits.
- EPSTL1, LGALS3P and TAGLN are involved in the structure and functional regulation of ECM.
- CXCL9 and CCL2 are chemokines with multiple functions including growth-promoting functions for tumor cells.
- chemoresistant refers to a tumor or cancer cell that shows little or no significant detectable therapeutic response to an agent used in chemotherapy.
- radioresistant refers to a tumor or cancer cell that shows little or no significant detectable therapeutic response to an agent used in radiotherapy such as ionizing radiation.
- chemosensitive refers to a tumor or cancer cell that shows a detectable therapeutic response to an agent used in chemotherapy.
- radiosensitive refers to a tumor or cancer cell that shows a detectable therapeutic response to an agent used in radiotherapy.
- chemotherapeutic agent As used herein, the phrases “chemotherapeutic agent,” “cytotoxic agent,” “anticancer agent,” and “antitumor agent” are used interchangeably and refer to an agent that has the effect of inhibiting the growth or proliferation, or inducing the killing, of a tumor or cancer cell.
- the chemotherapeutic agent may inhibit or reverse the development or progression of a tumor or cancer, such as for example, a solid tumor.
- chemotherapy refers to administration of at least one chemotherapeutic agent to a subject having a tumor or cancer.
- radiotherapy refers to administration of at least one “radiotherapeutic agent” to a subject having a tumor or cancer and refers to any manner of treatment of a tumor or cancer with a radiotherapeutic agent.
- a radiotherapeutic agent includes, for example, ionizing radiation including, for example, external beam radiotherapy, stereotatic radiotherapy, virtual simulation, 3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, ionizing particle therapy and radioisotope therapy.
- taxoid refers to a class of derivatives from taxol, which were developed for their anti-cancer properties. Taxoids are similar to taxanes. Taxoids may include taxotere.
- paclitaxel refers to a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel.
- Paclitaxel may be used to treat patients with lung, ovarian, breast, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel may be also used for the prevention of restenosis.
- Paclitaxel stabilizes microtubules and, as a result, interferes with the normal breakdown of microtubules during cell division. Together with docetaxel, it forms the drug category of the taxanes.
- Docetaxel refers to a clinically well-established anti-mitotic chemotherapy medication that works by interfering with cell division. Docetaxel is as generic or under the trade name Taxotere or Docecad. Docetaxel is approved by the FDA for treatment of locally advanced or metastatic breast cancer, head and neck cancer, gastric cancer, hormone-refractory prostate cancer and non small-cell lung cancer. Docetaxel can be used as a single agent or in combination with other chemotherapeutic drugs as indicated depending on specific cancer type and stage.
- Docetaxel is a member of the taxane drug class, which also includes the chemotherapeutic medication paclitaxel. Although docetaxel remains twice as potent as paclitaxel (due to docetaxel's effect on the centrosome of the mitotic spindle), the two taxanes have been observed to have comparable efficacy.
- cabazitaxel previously “XRP-6258,” or trade name “Jevtana,” as used herein, refers to a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on Jun. 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
- FDA U.S. Food and Drug Administration
- Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
- antiandrogen refers to any compound or substance which can prevent androgens from expressing their biological effects on responsive tissues. Antiandrogens may alter the androgen pathway by blocking the appropriate receptors, competing for binding sites on the cell's surface, or affecting androgen production. Antiandrogens can be prescribed to treat an array of diseases and disorders. In men, antiandrogens are most frequently used to treat prostate cancer. In women, antiandrogens are used to decrease levels of male hormones causing symptoms of hyperandrogenism. Antiandrogens present in the environment have become a topic of concern. Many industrial chemicals, pesticides and insecticides exhibit antiandrogenic effects. Certain plant species have also been found to produce antiandrogens. Environmental antiandrogens can have harmful effects on reproductive organ development in fetuses exposed in utero as well as their offspring.
- combination therapy (or “co-therapy”) embraces the administration of an agent used in JAK/STAT pathway inhibition and one or more of anticancer agents such as a chemotherapeutic agent and/or radiation therapy, as part of a specific treatment regimen intended to provide a beneficial effect from the co-action of the JAK/STAT pathway inhibitor and the other agent.
- the beneficial effect of the combination may include, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination.
- Administration of the combination typically is carried out over a defined time period (usually minutes, hours, days or weeks depending upon the combination selected).
- “Combination therapy” generally is not intended to encompass the administration of an agent as part of separate monotherapy regimens that incidentally and arbitrarily result in the combinations of the present invention. “Combination therapy” is intended to embrace administration of the agents in a sequential manner, that is, wherein the agents are administered at different times, as well as administration of the agents in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject concurrently with radiation therapy a single capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules for each therapeutic agent. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues.
- the therapeutic agents can be administered by the same route or by different routes.
- a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally.
- all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection.
- the sequence in which the agents are administered is not narrowly critical although radiation therapy typically will follow the administration of the JAK2 inhibitor.
- “Combination therapy” can also embrace the administration of the agents as described above in further combination with other biologically active ingredients (such as, but not limited to, an antineoplastic agent) and non-drug therapies (such as, but not limited to, surgery).
- the radiation treatment of the combination may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the agents is achieved. For example, in appropriate cases, the beneficial effect is still achieved even when the radiation treatment is temporally removed from the administration of the other agent, perhaps by days or even weeks.
- An illustrative antineoplastic agent or chemotherapeutic agent may include, for example, a standard taxane. Taxanes are produced by the plants of the genus Taxus and are classified as diterpenes and widely uses as chemotherapy agents including, for example, paclitaxel, (Taxol®, Bristol-Meyers Squibb, CAS 33069-62-4) and docetaxel (Taxotere®, Sanofi-Aventis, CAS 114977-28-5). Other chemotherapeutic agent may include semi-synthetic derivatives of a natural taxoid such as cabazitaxel (Jevtana®, Sanofi-Aventis, CAS 183133-96-2).
- chemotherapeutic agent may also include an androgen receptor inhibitor or mediator.
- Illustrative androgen receptor inhibitors may include, a steroidal antiandrogen (for example, cyperterone, CAS 2098-66-0); a non-steroidal antiandrogen (for example, flutamide, Eulexin®, Schering-Plough, CAS 13311-84-7); nilutamide (Nilandron®, CAS 63612-50-0); enzalutamide (Xtandi®, Medivation®, CAS 915087-33-1); bicalutamide (Casodex, AstraZeneca, CAS 90357-06-5); a peptide antiandrogen; a small molecule antiandrogen (for example, RU58642 (Roussel-Uclaf SA, CAS 143782-63-2); LG120907 and LG105 (Ligand Pharmaceuticals); RD162 (Medivation, CAS 915087-
- neoplastic agents or chemotherapeutic agents may include, for example: alkylating agents such as nitrogen mustards such as mechlorethamine (HN 2 ), cyclophosphamide, ifosfamide, melphalan (L-sarcolysin) and chlorambucil; ethylenimines and methylmelamines such as hexamethylmelamine, thiotepa; alkyl sulphonates such as busulfan; nitrosoureas such as carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU) and streptozocin (streptozotocin); and triazenes such as decarbazine (DTIC; dimethyltriazenoimidazole-carboxamide); antimetabolites including folic acid analogues such as methotrexate (amethopterin); pyrimidine analogue
- compositions herein may be formulated for oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal, injection/injectable, and/or parental (including subcutaneous, intramuscular, intravenous, and intradermal) administration. Other suitable administration routes are incorporated herein.
- the compositions may be presented conveniently in unit dosage forms and may be prepared by any methods known in the pharmaceutical arts. Examples of suitable drug formulations and/or forms are discussed in, for example, Hoover, John E. Remington's Pharmaceutical Sciences, Mack Publishing Co., Eston, Pa.; 18.sup.th edition (1995); and Liberman, H. A. and Lachman, L. Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.
- Illustrative methods may include the step of bringing one or more active ingredients into association with a carrier that constitutes one or more accessory ingredients.
- the compositions may be prepared by bringing into association uniformly and intimately one or more active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
- compositions may include those suitable for oral, intramuscular, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
- compositions and unit dosages thereof may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
- Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- a salt may be a pharmaceutically suitable (i.e., pharmaceutically acceptable) salt including, but not limited to, acid addition salts formed by mixing a solution of the instant compound with a solution of a pharmaceutically acceptable acid.
- a pharmaceutically acceptable acid may be, for example, hydrochloric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- Suitable pharmaceutically-acceptable salts may further include, but are not limited to salts of pharmaceutically-acceptable inorganic acids, including, for example, sulfuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically-acceptable organic acids such propionic, butyric, maleic, hydroxymaleic, lactic, mucic, gluconic, benzoic, succinic, phenylacetic, toluenesulfonic, benezenesulfonic, salicyclic sulfanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic, and valeric acids.
- pharmaceutically-acceptable inorganic acids including, for example, sulfuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids
- Various pharmaceutically acceptable salts may include, for example, the list of FDA-approved commercially marketed salts including acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, mitrate, pamoate, pantothenate, phosphate, diphosphate, polygal
- a hydrate may be a pharmaceutically suitable (i.e., pharmaceutically acceptable) hydrate that is a compound formed by the addition of water or its elements to a host molecule (for example, the free form version of the compound) including, but not limited to, monohydrates, dihydrates, etc.
- a solvate may be a pharmaceutically suitable (i.e., pharmaceutically acceptable) solvate, whereby solvation is an interaction of a solute with a solvent which leads to stabilization of the solute species in a solution, and whereby the solvated state is an ion in a solution complexed by solvent molecules.
- Solvates and hydrates may also be referred to as “analogues.”
- a prodrug may be a compound that is pharmacologically inert but is converted by enzyme or chemical action to an active form of the drug (i.e., an active pharmaceutical ingredient) at or near the predetermined target site.
- prodrugs are inactive compounds or partially active compounds that yield an active compound upon metabolism in the body, which may or may not be enzymatically controlled.
- Prodrugs may also be broadly classified into two groups: bioprecursor and carrier prodrugs. Prodrugs may also be subclassified according to the nature of their action. Bioprecursor prodrugs are compounds that already contain the embryo of the active species within their structure, whereby the active species are produced upon metabolism.
- Carrier prodrugs are formed by combining the active drug (e.g., active ingredient) with a carrier species forming a compound having desirable chemical and biological characteristics, whereby the link is an ester or amide so that the carrier prodrug is easily metabolized upon absorption or delivery to the target site.
- the link is an ester or amide so that the carrier prodrug is easily metabolized upon absorption or delivery to the target site.
- lipophilic moieties may be incorporated to improve transport through membranes.
- Carrier prodrugs linked by a functional group to carrier are referred to as bipartite prodrugs.
- Prodrugs where the carrier is linked to the drug by a separate structure are referred to as tripartite prodrugs, whereby the carrier is removed by an enzyme-controlled metabolic process, and whereby the linking structure is removed by an enzyme system or by a chemical reaction.
- a hydroxy-protecting group includes, for example, a tert-butyloxy-carbonyl (t-BOC) and t-butyl-dimethyl-silyl (TBS).
- t-BOC tert-butyloxy-carbonyl
- TBS t-butyl-dimethyl-silyl
- Other hydroxy protecting groups contemplated are known in the art.
- a dosage form and/or composition may include one or more active metabolites of the active ingredients in place of or in addition to the active ingredients disclosed herein.
- Dosage form compositions containing the active ingredients may also contain one or more inactive pharmaceutical ingredients such as diluents, solubilizers, alcohols, binders, controlled release polymers, enteric polymers, disintegrants, excipients, colorants, flavorants, sweeteners, antioxidants, preservatives, pigments, additives, fillers, suspension agents, surfactants (for example, anionic, cationic, amphoteric and nonionic), and the like.
- Various FDA-approved topical inactive ingredients are found at the FDA's “The Inactive Ingredients Database” that contains inactive ingredients specifically intended as such by the manufacturer, whereby inactive ingredients can also be considered active ingredients under certain circumstances, according to the definition of an active ingredient given in 21 CFR 210.3(b)(7). Alcohol is a good example of an ingredient that may be considered either active or inactive depending on the product formulation.
- an oral dosage form may include capsules (a solid oral dosage form consisting of a shell and a filling, whereby the shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band and whereby capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed), capsule or coated pellets (solid dosage form in which the drug is enclosed within either a hard or soft soluble container or “shell” made from a suitable form of gelatin; the drug itself is in the form of granules to which varying amounts of coating have been applied), capsule coated extended release (a solid dosage form in which the drug is enclosed within either a hard or soft soluble container or “shell” made from a suitable form of gelatin; additionally, the capsule is covered in a designated coating, and which releases a drug or drugs in such a manner to allow at least a reduction in dosing frequency as compared to that drug or drugs
- Oral dosage forms contemplated herein also include granules (a small particle or grain), pellet (a small sterile solid mass consisting of a highly purified drug, with or without excipients, made by the formation of granules, or by compression and molding), pellets coated extended release (a solid dosage form in which the drug itself is in the form of granules to which varying amounts of coating have been applied, and which releases a drug or drugs in such a manner to allow a reduction in dosing frequency as compared to that drug or drugs presented as a conventional dosage form), pill (a small, round solid dosage form containing a medicinal agent intended for oral administration), powder (an intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use), elixir (a clear, pleasantly flavored, sweetened hydroalcoholic liquid containing dissolved medicinal agents; it is intended for oral use), chewing gum (a sweetened and flavored insoluble plastic material of various shapes which when chewed, releases a drug substance into the oral cavity),
- Oral dosage forms contemplated herein may further include a tablet (a solid dosage form containing medicinal substances with or without suitable diluents), tablet chewable (a solid dosage form containing medicinal substances with or without suitable diluents that is intended to be chewed, producing a pleasant tasting residue in the oral cavity that is easily swallowed and does not leave a bitter or unpleasant after-taste), tablet coated (a solid dosage form that contains medicinal substances with or without suitable diluents and is covered with a designated coating), tablet coated particles (a solid dosage form containing a conglomerate of medicinal particles that have each been covered with a coating), tablet delayed release (a solid dosage form which releases a drug or drugs at a time other than promptly after administration, whereby enteric-coated articles are delayed release dosage forms), tablet delayed release particles (a solid dosage form containing a conglomerate of medicinal particles that have been covered with a coating which releases a drug or drugs at a time other than promptly after administration, whereby enteric-coated articles are delayed release dosage forms), tablet delayed release
- Injection and infusion dosage forms include, but are not limited to, the following.
- Liposomal injection includes or forms liposomes or a lipid bilayer vesicle having phospholipids that encapsulate an active drug substance.
- Injection includes a sterile preparation intended for parenteral use.
- Emulsion injection includes an emulsion comprising a sterile, pyrogen-free preparation intended to be administered parenterally.
- Lipid complex and powder for solution injection are sterile preparations intended for reconstitution to form a solution for parenteral use.
- Powder for suspension injection is a sterile preparation intended for reconstitution to form a suspension for parenteral use.
- Powder lyophilized for liposomal suspension injection is a sterile freeze dried preparation intended for reconstitution for parenteral use that is formulated in a manner allowing incorporation of liposomes, such as a lipid bilayer vesicle having phospholipids used to encapsulate an active drug substance within a lipid bilayer or in an aqueous space, whereby the formulation may be formed upon reconstitution.
- Powder lyophilized for solution injection is a dosage form intended for the solution prepared by lyophilization (“freeze drying”), whereby the process involves removing water from products in a frozen state at extremely low pressures, and whereby subsequent addition of liquid creates a solution that conforms in all respects to the requirements for injections.
- Powder lyophilized for suspension injection is a liquid preparation intended for parenteral use that contains solids suspended in a suitable fluid medium, and it conforms in all respects to the requirements for Sterile Suspensions, whereby the medicinal agents intended for the suspension are prepared by lyophilization.
- Solution injection involves a liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
- Solution concentrate injection involves a sterile preparation for parenteral use that, upon addition of suitable solvents, yields a solution suitable for injections.
- Suspension injection involves a liquid preparation (suitable for injection) containing solid particles dispersed throughout a liquid phase, whereby the particles are insoluble, and whereby an oil phase is dispersed throughout an aqueous phase or vice-versa.
- Suspension liposomal injection is a liquid preparation (suitable for injection) having an oil phase dispersed throughout an aqueous phase in such a manner that liposomes (a lipid bilayer vesicle usually containing phospholipids used to encapsulate an active drug substance either within a lipid bilayer or in an aqueous space) are formed.
- Suspension sonicated injection is a liquid preparation (suitable for injection) containing solid particles dispersed throughout a liquid phase, whereby the particles are insoluble.
- the product may be sonicated as a gas is bubbled through the suspension resulting in the formation of microspheres by the solid particles.
- a parenteral carrier system may include one or more pharmaceutically suitable excipients, such as solvents and co-solvents, solubilizing agents, wetting agents, suspending agents, thickening agents, emulsifying agents, chelating agents, buffers, pH adjusters, antioxidants, reducing agents, antimicrobial preservatives, bulking agents, protectants, tonicity adjusters, and special additives.
- pharmaceutically suitable excipients such as solvents and co-solvents, solubilizing agents, wetting agents, suspending agents, thickening agents, emulsifying agents, chelating agents, buffers, pH adjusters, antioxidants, reducing agents, antimicrobial preservatives, bulking agents, protectants, tonicity adjusters, and special additives.
- Inhalation dosage forms may include, but are not limited to, aerosol being a product that is packaged under pressure and contains therapeutically active ingredients that are released upon activation of an appropriate valve system intended for topical application to the skin as well as local application into the nose (nasal aerosols), mouth (lingual and sublingual aerosols), or lungs (inhalation aerosols).
- aerosol being a product that is packaged under pressure and contains therapeutically active ingredients that are released upon activation of an appropriate valve system intended for topical application to the skin as well as local application into the nose (nasal aerosols), mouth (lingual and sublingual aerosols), or lungs (inhalation aerosols).
- Inhalation dosage forms further include foam aerosol being a dosage form containing one or more active ingredients, surfactants, aqueous or nonaqueous liquids, and the propellants, whereby if the propellant is in the internal (discontinuous) phase (i.e., of the oil-in-water type), a stable foam is discharged, and if the propellant is in the external (continuous) phase (i.e., of the water-in-oil type), a spray or a quick-breaking foam is discharged.
- foam aerosol being a dosage form containing one or more active ingredients, surfactants, aqueous or nonaqueous liquids, and the propellants, whereby if the propellant is in the internal (discontinuous) phase (i.e., of the oil-in-water type), a stable foam is discharged, and if the propellant is in the external (continuous) phase (i.e., of the water-in-oil type), a spray or a quick-breaking foam is
- Inhalation dosage forms may also include metered aerosol being a pressurized dosage form consisting of metered dose valves which allow for the delivery of a uniform quantity of spray upon each activation; powder aerosol being a product that is packaged under pressure and contains therapeutically active ingredients, in the form of a powder, that are released upon activation of an appropriate valve system; and aerosol spray being an aerosol product which utilizes a compressed gas as the propellant to provide the force necessary to expel the product as a wet spray and being applicable to solutions of medicinal agents in aqueous solvents.
- metered aerosol being a pressurized dosage form consisting of metered dose valves which allow for the delivery of a uniform quantity of spray upon each activation
- powder aerosol being a product that is packaged under pressure and contains therapeutically active ingredients, in the form of a powder, that are released upon activation of an appropriate valve system
- aerosol spray being an aerosol product which utilizes a compressed gas as the propellant to provide the force necessary to expel the product as a wet spray and being applicable
- Pharmaceutically suitable inhalation carrier systems may include pharmaceutically suitable inactive ingredients known in the art for use in various inhalation dosage forms, such as (but not limited to) aerosol propellants (for example, hydrofluoroalkane propellants), surfactants, additives, suspension agents, solvents, stabilizers and the like.
- aerosol propellants for example, hydrofluoroalkane propellants
- surfactants for example, surfactants, additives, suspension agents, solvents, stabilizers and the like.
- a transdermal dosage form may include, but not limited to, a patch being a drug delivery system that often contains an adhesive backing that is usually applied to an external site on the body, whereby the ingredients either passively diffuse from, or are actively transported from some portion of the patch, and whereby depending upon the patch, the ingredients are either delivered to the outer surface of the body or into the body; and other various types of transdermal patches such as matrix, reservoir and others known in the art.
- the “pharmaceutically suitable transdermal carrier system” may include pharmaceutically suitable inactive ingredients known in the art for use in various transdermal dosage forms, such as (but not limited to) solvents, adhesives, diluents, additives, permeation enhancing agents, surfactants, emulsifiers, liposomes, and the like.
- Suitable dosage amounts and dosing regimens may be selected in accordance with a variety of factors, including one or more particular conditions being treated, the severity of the one or more conditions, the genetic profile, age, health, sex, diet, and weight of the subject, the route of administration alone or in combination with pharmacological considerations including the activity, efficacy, bioavailability, pharmacokinetic, and toxicological profiles of the particular compound employed, whether a drug delivery system is utilized and whether the drug is administered as part of a drug combination. Therefore, the dosage regimen to be employed may vary widely and may necessarily deviate from the dosage regimens set forth herein.
- Contemplated dosage forms may include an amount of one or more JAK/STAT pathway inhibitors ranging from about 1 to about 1200 mg, or about 5 to about 100 mg, or about 25 to about 800 mg, or about 100 to about 500 mg, or 0.1 to 50 milligrams ( ⁇ 10%), or 10 to 100 milligrams ( ⁇ 10%), or 5 to 500 milligrams ( ⁇ 10%), or 0.1 to 200 milligrams ( ⁇ 10%), or 1 to 100 milligrams ( ⁇ 10%), or 5 to 50 milligrams ( ⁇ 10%), or 30 milligrams (+10%), or 20 milligrams ( ⁇ 10%), or 10 milligrams ( ⁇ 10%), or 5 milligrams ( ⁇ 10%), per dosage form, such as, for example, a tablet, a pill, a bolus, and the like.
- JAK/STAT pathway inhibitors ranging from about 1 to about 1200 mg, or about 5 to about 100 mg, or about 25 to about 800 mg, or about 100 to about 500 mg, or
- a dosage form may be administered to a subject in need thereof once per day, or twice per day, or once every 6 hours, or once every 4 hours, or once every 2 hours, or hourly, or twice an hour, or twice a day, or twice a week, or monthly.
- terapéuticaally effective is intended to qualify the amount that will achieve the goal of improvement in disease severity and/or the frequency of incidence over non-treatment, while limiting, reducing, or avoiding adverse side effects typically associated with disease therapies.
- a “therapeutic effective” amount relieves to some extent one or more of the symptoms of a cancer disease or disorder.
- a therapeutic effect refers to one or more of the following: 1) reduction in the number of cancer cells by, for example, killing the cancer cells; 2) reduction in tumor size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cancer cell infiltration into peripheral organs; 4) inhibition (i.e., slowing to some extent, preferably stopping) of tumor metastasis; 5) inhibition, to some extent, of tumor growth; 6) relieving or reducing to some extent one or more of the symptoms associated with the disorder; and/or 7) relieving or reducing the side effects associated with the administration of anticancer agents.
- “Therapeutic effective amount” is intended to qualify the amount required to achieve a therapeutic effect.
- a therapeutically effective amount of a JAK/STAT pathway inhibitor may be any amount that begins to improve cancer treatment in a subject either administered alone or in combination with another therapeutic agent.
- an effective amount of an inhibitor used in the therapeutic regime described herein may be, for example, about 1 mg, or about 5 mg, or about 10 mg, or about 25 mg, or about 50 mg, or about 100 mg, or about 200 mg, or about 400 mg, or about 500 mg, or about 600 mg, or about 1000 mg, or about 1200 mg, or about 1400 mg, or from about 10 to about 60 mg, or about 50 mg to about 200 mg, or about 150 mg to about 600 mg per day.
- an effective amount of an inhibitor used herein may be that which results in a detectable blood level of above about 1 ng/dL, 5, ng/dL, 10 ng/dL, 20, ng/dL, 35 ng/dL, or about 70 ng/dL, or about 140 ng/dL, or about 280 ng/dL, or about 350 ng/dL, or lower or higher.
- pharmaceutically acceptable is used herein to mean that the modified noun is appropriate for use in a pharmaceutical product.
- Pharmaceutically acceptable cations include metallic ions and organic ions.
- Other metallic ions may include, but are not limited to appropriate alkali metal salts, alkaline earth metal salts and other physiological acceptable metal ions.
- Exemplary ions may include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc in their usual valences.
- Organic ions may include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
- Pharmaceutically acceptable acids may include without limitation hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.
- one active ingredient may be in an extended release form, while an optional second, third, or fourth other active ingredient, for example, may or may not be, so the recipient experiences, for example, a spike in the second, third, or fourth active ingredient that dissipates rapidly, while the first active ingredient is maintained in a higher concentration in the blood stream over a longer period of time.
- one of the active ingredients may be an active metabolite, while another may be in an unmetabolized state, such that the active metabolite has an immediate effect upon administration to a subject whereas the unmetabolized active ingredient administered in a single dosage form may need to be metabolized before taking effect in the subject.
- solid form preparations that include at least one active ingredient which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms may include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. Solutions or suspensions may be applied topically and/or directly to the nasal cavity, respiratory tract, eye, or ear by conventional means, for example with a dropper, pipette or spray.
- one or more of the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
- a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
- PVP polyvinylpyrrolidone
- the powder carrier may form a gel in the nasal cavity.
- the powder composition may be presented in unit dose form, for example, in capsules or cartridges of, for example, gelatin, or blister packs from which the powder may be administered by means of an inhaler.
- the pharmaceutical preparations may be in unit dosage forms.
- the preparation may be subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, such as a kit or other form, the package containing discrete quantities of preparation, such as packeted tablets, capsules, liquids or powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge, or it can be the appropriate number of any of these in packaged form.
- cell lines were characterized for relative radioresistance using a clonogenic assay. Briefly, the cells were cultured in their appropriate media at 5% CO2 at 37° C. Optimal cell plating concentrations for a p60 dish were determined for each cell line. The majority of cell lines were plated in triplicate at concentrations of 100 cells/plate for control, 1000 cells/plate for 2 Gy, 2000 cells/plate for 5 Gy, and 3000 cells/plate for 8 Gy. Plates were irradiated 24 hours after plating with either 2, 5, or 8 Gy using a irradiated using a Nordion Gammacell 60 Co irradiator operating at a dose rate of ⁇ 18 Gy/minute.
- cDNA was synthesized as described previously (see, Khodarev N N, Yu J, Nodzenski E, et al. Method of RNA purification from endothelial cells for DNA array experiments. Biotechniques2002; 32: 316-20).
- GAPDH was used for the internal control.
- PCR was done for 40 cycles at 95° C. for 15 s and 60° C. for 1 min after initial incubations at 50° C. for 2 min and 95° C. for 10 min using SYBR Green PCR reagent in ABI 7700 System (Applied Biosystems).
- ⁇ Ct values were calculated according to the manufacturer's instructions. Fold induction/suppression relative to GAPDH was calculated as 2 ⁇ ct .
- Total cellular protein was extracted in radioimmunoprecipitation assay buffer with protease inhibitors added (1 ⁇ PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L Na 3 VO 4 , 2 ⁇ g/mL aprotinin, 1 mmol/L phenylmethylsulfonyl fluoride). All samples were normalized by protein concentration using Bradford reagent and standard solution of bovine serum albumin (1 mg/mL). Concentration of all samples was adjusted to 1 mg/mL and equal amount of protein was loaded in each well. For total proteins, 10 ⁇ g of protein was loaded per well.
- Proteins were separated on 7.5%-12% SDS-PAGE (depending on molecular mass of protein) and transferred to polyvinylidene difluoride membranes (PVDF). Total proteins were detected using the rabbit or goat primary Abs.
- VDF polyvinylidene difluoride membranes
- the antibodies for actin (I-19) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; FL-335) were used. All antibodies were purchased from Santa Cruz Biotechnology. Images were quantified with ImageJ software by integration pixel values across the area of specific bands.
- This gene set was subsequently analysed using Ingenuity Pathway Analysis software, which highlighted the importance of the JAK/STAT signalling in the radiation response of prostate cancer.
- one of the potential up-stream regulator is IL6 and IFN-gamma, which through activation of JAK kinases involve STAT3, STAT2 and IRF1/IRF8 genes.
- Another important node is STAT1/STAT2 activation being linked to the greatest number of differentially up-regulated genes following radiotherapy ( FIG. 1 ).
- mice 10 7 cells were injected in the right flank of each nude mice (5 animals per group) and when tumors reached 200 mm 3 in volume mice were either left un-treated, or treated with SAR302503 (120 mg/kg, once a day, 4 days) or irradiated locally (2 ⁇ 10 Gy) or subjected to combined treatments with SAR302503 and IR.
- SAR302503 120 mg/kg, once a day, 4 days
- IR irradiated locally
- MCL1 is a Significant Downstream Mediator of the JAK/STAT Survival Pathway in Prostate Cancer Cells
- CWR-R1 and CWR-22RV1 cells were tested with gamma radiation after transfection with a panel of 86 siRNA's to previously reported members of the JAK/STAT signaling pathway.
- the final screen was conducted as follows: On day 1, Lipofectamine RNAiMAX 0.075 ⁇ L/well diluted in Opti-MEM (Life Technologies) was added using a Tecan Freedom EVO 200 robotic liquid handling station to previously prepared 384-well microplates (Corning/3712) containing immobilized pooled siRNAs (Dharmacon siGENOME) plated in triplicate for each target gene.
- Luminescent reagent was added using a Thermo Electron MultiDrop Combi, and luminescent measurements was taken 90 minutes later using Molecular Devices Analyst GT.
- Table No. 1 lists the genes presented in FIG. 4 ( FIGS. 4A and 4B ). This is different than in cell lines derived from other malignancies for which MCL1 is not one of the top 10 genes selected.
- MCL1 is recognized as one of the most common oncogenes amplified in various cancers, including prostate cancer (Beroukhim R, Mermel C H, Porter D, et al: The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905, 2010).
- MCL1 may be an additional therapeutic target.
- apical suppressor of RNA-dependent IFN beta production DHX58 (LGP2) IFN-dependent isopeptidase USP18 and proteosome subunits PSMB8 and PSMB10 were among genes which suppression significantly suppressed viability of prostate cancer cell lines. _These genes can also be used as additional down-stream targets but besides their expression can be associated with sensitivity of the individual prostate tumors to SAR302503.
- FIG. 4A FIG. 4B CW22Rv1 + IR CWRR1 + IR MCL1 MCL1 LGALS3BP IRF9 RNF213 USP18 PLSCR1 LGALS3BP DDX60L OASL OASL HERC5 IFITM3 CXCL9 IFIH1 PSMB10 CXCL1 DDX60 WARS ISG15 DDX60 PLSCR1 IFITM1 TRIM21 SAMHD1 SP110 DHX58 TAP1 CXCL9 IFIH1 USP18 B2M DTX3L IFITM3 TRIM21 DTX3L PSMB10 DHX58 EPSTI1 VAMP5 SP110 GBP1 PRIC285 CCL2 IRF9 HERC6 IFI27 TPD52L1 PARP12 WARS IFIT2 EPSTI1 PSMB8 IFITM1 HERC6 IFITM2 BST2 IFI27 MGP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more inhibitors of the JAK/STAT pathway which renders the cancer chemosensitive and/or radiosensitive.
Description
- This application claims benefit from U.S. Provisional Application 61/842,045, filed Jul. 2, 2013, which is incorporated herein by reference for all purposes.
- Not applicable
- 1. Field of the Invention
- The present invention relates to the identification and control of the JAK/STAT pathway for treatment of cancers, including chemoresistant and/or radioresistant cancers.
- 2. Description of the Background of the Invention
- Prostate cancer is the second leading cause of cancer-related death in men with more than 28,000 Americans dying annually. In order for a cancer to be “successful” in the host it must survive typical oncogenic processes, as well as treatment regimens including iatrogenic insults, including androgen ablation, the more recently approved potent androgen receptor (AR) targeted agents, and often radiotherapy and taxane-based chemotherapy as well. A locally advanced prostate cancer and metastatic castrate resistant prostate cancer (mCRPC) also regularly develop resistance to the cytotohic host microenviroment and genotoxic anti-tumor therapy.
- Just as importantly, prostate cancer tends to metastasize to bone, leading to significant morbidity and functional limitations prior to its lethal effects. Despite this burden, it is a cancer for which a number of localized and systemic therapies are available and in fact is an example of the success of molecular targeted oncology treatment. More specifically, it was recognized more than half a century ago that prostate cancer is driven by the androgen receptor (AR) and this has led to the recent development of several more potent androgen receptor pathway directed therapies to supplement traditional surgical or medical castration. In addition to androgen receptor targeted treatments, more traditional DNA and DNA-repair targeted therapies have also been shown to be modestly effective in improving survival or ameliorating symptoms in this disease including the tubule targeted agents docetaxel and cabazitaxel, and radiotherapy with alpha (Ra233), beta (Sr89), and gamma (photon) particles.
- The mortality burden nevertheless emphasizes the fact that these therapies are not curative and that this cancer continually evolves a resistant phenotype, which is broadly categorized as metastatic castrate-resistant prostate cancer (mCRPC), and which is ultimately the lethal phenotype. Aggressive prostate cancer is resistant to cytotoxic stimuli of microenviroment and uses yet elusive mechanisms to colonize distant sites. Although these events are likely to be important in many, if not all, human cancers, the relatively long natural history of prostate cancer and the variety of therapies typically utilized suggest that such adaptation is especially relevant to mCRPC and may use unique pathways.
- Further advances in the treatment of prostate cancer, and especially systemic therapy of advanced local disease and mCRPC, must therefore take into account and target the fundamental survival pathways that the resistant cell utilizes. This concept has been previously applied to various investigational therapeutic approaches by attempting to target apoptosis, necrosis, and autophagy pathways as the presumptive final common pathway(s) for cellular death. To date these have met with only limited success, which may be due to the non-specific nature of the targeting agents, the multiple death pathways cells can follow, and the likelihood that activated survival pathways are context specific to tumor type and histology.
- Targeting survival pathways in conjunction with traditional cytotoxic therapies has been previously attempted and continues to be an area of therapeutic investigation. Elucidation of the significance and role of the JAK/STAT pathway in oncogenesis is an area of fundamental and translational research as well and has been identified as altered in multiple epithelial malignancies. Furthermore, JAK targeted therapy is being investigated for the treatment of myeloproliferative diseases. For example, Ruxolitinib (INCB018424, trade names Jakafi® and Jakavi®, by Incyte Pharmaceuticals and Novartis, CAS 941678-49-5) was developed for the treatment of intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It is also being investigated for the treatment of lymphomas and pancreatic cancer, polycythemia vera, and plaque psoriasis. However, the JAK/STAT pathway is not being investigated in prostate cancer as a potentially targetable survival pathway for which inhibition, in conjunction with other lethal insults, may be clinically pragmatic. Further, a number of mCRPC treatments targeting various androgen receptor and non-androgen receptor pathways are in development, but are expected to be limited by the fundamental activation of specific survival pathways in this disease.
- While the importance of the JAK/STAT pathway, in general, for cancers continues to be investigated, the role it plays in tumors remains undefined. Consequently, there is an urgent and definite need to identify therapies that may potentially have a role in tumor development associated with the JAK/STAT pathway. Such therapies may provide new treatments for JAK/STAT-related cancers, and/or therapies targeted to the sensitization of cancers for chemotherapies and/or radiotherapies. Targeting JAK/STAT could thus inhibit a fundamental property of the malignant phenotype and open the door to multiple therapies, including combination therapy. Therefore, there is a need to determine the role of the JAK/STAT pathway in cancer, including solid tumors, which may play a role in developing effective new therapies for treating cancers around the JAK/STAT pathway. There is also a need to determine the most relevant members of the JAK/STAT signaling pathway for the survival cancer phenotype, leading to the identification of the most relevant target(s), and the most promising predictive biomarker(s). More effective and targeted cancer therapies with potentially fewer side effects are also needed.
- A first aspect of the invention provides a method of treating a subject with a chemoresistant or radioresistant prostate cancer. The method comprises administering a therapeutically effective amount of an inhibitor of a JAK/STAT pathway to the subject.
- In another embodiment, the cancer is associated with activation of a JAK/STAT-related pathway.
- Illustratively, JAK includes a JAK1, a JAK2, a JAK3 or a Tyk2 kinase, and the STAT includes a STAT1, a STAT2, a STAT3, a STAT4, a STAT5, or a STAT6 transcriptional factor
- In one embodiment, the inhibitor of the JAK/STAT pathway inhibits at least one of a JAK, and consequently at least one of a STAT.
- In another embodiment, the prostate cancer has an amplified level of MCL1 or LGP2 (DHX58) or immunoproteasome subunits PSMB8, 9, 10 expression as compared to a normal control cell.
-
FIG. 1 shows the results of a gene profiling experiment using Affymetrix microarrays on PC3 prostate cancer mouse xenografts following irradiation; -
FIG. 2 shows the effect of JAK2 inhibitor SAR302503 in prostate cancer cell lines CWRR1 and CW22Rv1 treated with gamma radiation; -
FIG. 3 shows the effect of JAK2 inhibitor SAR302503 in prostate cancer xenografts treated with gamma radiation; and -
FIG. 4 (presented asFIGS. 4A and 4B ) shows that expression of MCL1, USP18, DHX58 (LGP2) and PSMB8 and 10 confers post-radiation survival of prostate cancer cell lines CWRR1 and CW22Rv1. Table No. 1, below, lists the genes presented inFIG. 4 (FIGS. 4A and 4B ). - Treatment of a cancer in a subject in need thereof is provided herein, as are compositions, combinations, kits, and methods for treating cancer, and methods for identifying inhibitors of the JAK/STAT pathway having a role in the treatment of cancer and therapies to treat cancer based on this pathway. A JAK/STAT dependent cancer may include any solid tumor, including lung, prostate, head and neck, breast and colorectal cancer, melanomas and gliomas, and the like. While the present disclosure may be embodied in different forms, several specific embodiments are discussed herein with the understanding that the present disclosure is to be considered only an exemplification and is not intended to limit the invention to the illustrated embodiments.
- JAK kinases are associated with a variety of cytokine and growth factor receptors, and signal through several down-stream STAT homologs; however, the specific signaling pathways are quite complex and difficult to predict from disease to disease. For example receptors that are known to operate predominantly through JAK-dependent activation of a specific STAT protein, such as STAT1 through IFN-γ receptor activation or STAT3 through IL6/IL6R receptor gp130 activation can cross-activate alternative STATS. This may occur through JAK cross-phosphorylation as has been demonstrated in the context of IFN-γ signaling in which cross phosphorylation of JAK1 and JAK2 has been demonstrated. Additional complexities of the JAK/STAT signaling pathway are introduced by the extensive interactions between different STATS. For example, STAT1 and STAT3 can form heterodimers both in the phosphorylated and non-phosphorylated forms. Further, STAT1 and STAT3 can both bind to the same promoter sequences of the same genes (including oncogenes MUC1 and MCL1). Therefore, although the JAK/STAT signaling pathway may have been previously described in other diseases including some specific cancers, the correlation to other diseases and cancers and its complex interactions cannot be readily ascertained by reference only to this other previously described disease or cancer.
- The interactions between JAK and STAT components of this signaling pathway are complex. The development of small molecules and peptide inhibitors of individual JAK kinases and STAT proteins is rather rapid. Therefore, it is important to evaluate functional consequences of the inhibition of individual members of this cascade in a target cancer for which the effects have not been determined such as in prostate cancer. Further, the specific JAK and STAT proteins, as well as the relevant upstream and downstream mediators appear to differ across the cancer spectrum. The majority of investigations into the biology and role of the JAK/STAT pathway do not necessarily consider this subtlety. This reality challenges the contemporary notion that these survival pathways are homogeneous in various cancers. It is therefore, contemplated herein to identify the unique and specific components critical to the cancer survival phenotype related to the JAK/STAT pathway. For example, the inhibition of JAK2 (via knockdown) has different effects in prostate cancer cells under normal androgen levels, vs. castrate (low), vs. castrate-resistant-like androgen levels (no androgens present) (see, Martinez H., et al., Androgen-Sensitive Microsomal Signaling Networks Couples to the Proliferation and Differentiation of Human Prostate Cancer Cells, Genes & Cancer 2(10) 956-978). It has been noted that “[i]nterestingly, quantifiable differences in cell proliferation were not observed in knock-down cells cultured under conditions of androgen depletion.” (Id., at 968) Therefore, since the inhibition of JAK has different effects on prostate cancer cell proliferation, depending on androgen availability, one skilled in the art would not anticipate that JAK2 inhibitors would necessarily have the same effect on androgen-sensitive (under normal androgen levels) and androgen-resistant prostate cancer cells. Further, in a review article by Shodeinde and Barton (Shodeinde A. and B. Barton, Potential Use of STAT3 Inhibitors in Targeted Prostate Cancer Therapy: Future Prospects, OncoTargets and
Therapy 3 Jul. 2012), the dual JAK1/JAK2 inhibitor ruxtolitinib failed to show efficacy in a Phase II clinical trial with androgen-independent prostate cancer. As this dual JAK1/JAK2 inhibitor did not work in patients with androgen-independent prostate cancer, it would not be readily expected by one skilled in the art that a JAK2 inhibitor alone would work either. However, by investigating the complex interactions between JAK and STAT components of this signaling pathway it is contemplated that specific inhibition of JAK2, either alone or in combination with one or more anticancer agents, such as radiotherapy, for example, will be effective in treating prostate cancer in a subject. - Further, the JAK/STAT pathway is not being investigated in prostate cancer as a potentially targetable survival pathway for which inhibition, and possibly in conjunction with other lethal insults such as combination therapy may be clinically pragmatic. A number of mCRPC treatments targeting various androgen receptor and non-androgen receptor pathways are in development, but are expected to be limited by the fundamental activation of specific survival pathways in this disease. Targeting JAK/STAT could thus inhibit a fundamental property of the malignant phenotype and open the door to multiple therapies including, for example, combination therapy.
- Applicants' results suggest that the specifics of JAK/STAT survival pathway signaling are context and disease specific. The specific JAK and STAT proteins family members, as well as the relevant upstream and downstream mediators appear to differ across the cancer spectrum. The majority of previous investigations into the biology and role of the JAK/STAT pathway do not necessarily consider this subtlety. Applicants' hypothesis, therefore, challenges the notion that these survival pathways are homogeneous in various cancers and seeks to identify the unique and specific components critical to one illustrative cancer, the mCRPC survival phenotype.
- Based on the above discussion, Applicants describe several illustrative approaches to determine the JAK/STAT pathway survival mechanisms specific to a particular cancer, prostate cancer. Applicants envision that such approaches can be used in other cancer targets to determine the role of this pathway on cancer survival. Such approaches described herein include:
-
- a) Dissection of the relative impact of JAK1 vs. JAK2 and STAT1 vs. STAT3 on JAK/STAT-dependent tumor survival, and/or
- b) Validate MCL1 (Myeloid Cell Leukemia sequence 1; Entrez Gene ID for Human: 4170; HGNC ID: 6943; Ensembl ID: ENSG000001433847; OMIM ID: 1595525; UniProtKB ID: Q078203) as a down-stream mediator of JAK/STAT-dependent survival pathways and as a potential additional target for radio/chemosensitization of hormone-resistant prostate cancer.
- Using mCRPC as an example, a “successful” cancer in a subject, has survived a myriad of insults that would be expected to be lethal to most cells. Applicants now show that certain cellular survival pathways are upregulated and highly active in mCRPC. It is expected that such cells would be resistant to further lethal insults (for example, chemotherapy and/or radiotherapy) and successful therapy may employ the addition of a survival pathway inhibitor. The survival pathway in such cancers, including those that are chemoresistant and/or radioresistant, is believed to be the JAK/STAT pathway, which may include, for example, the JAK2/STAT1-STAT3 signaling members. Furthermore, it is also believed that the anti-apoptotic protein MCL1 is a downstream mediator of this survival pathway. It is further expected that the JAK/STAT pathway maintains cancer cell survival status and is, therefore, a viable therapeutic target. One approach is to determine JAK/STAT pathway survival mechanisms in a particular cancer. By utilizing a combination of sh/siRNA and chemical approaches with JAK2 specific and broader JAK1/2 inhibitors in genetically related cancer cell lines, for example, CWRR1 (resistant to JAK2 inhibition) and CW22RV1 (sensitive to JAK2 inhibition) in prostate cancer, the relative contributions of JAK1 and JAK2 can be determined as well as the relative contribution of STAT1 versus STAT3 in mediating survival. Further, the role of MCL1 as an effector of the JAK/STAT survival pathway in the particular cancer can also be evaluated.
- For example, Applicants have now shown that in hormone resistant prostate cancer cells, sensitive to JAK inhibitors, JAK2 inhibitors alone can suppress tumor growth and in combination with ionizing radiation lead to significant suppression of tumor growth (
FIGS. 1 and 2 ). Based on this observation, a JAK2 inhibitor can be used as primary therapy in patients with hormone resistant prostate cancer (localized) and/or treatment of hormone refractory metastatic prostate cancer for cure or palliation in combination with radio isotopes such as summerium and radium 223, which are employed in metastatic hormone refractory cancer. - Another approach is to develop combination therapy that includes JAK inhibitor therapies. For example, it is contemplated that JAK2 inhibition will enhance classic cytotoxic therapy, such as the standard taxanes. Taxanes are produced by the plants of the genus Taxus and are classified as diterpenes and widely used as chemotherapy agents including, for example, paclitaxel (Taxol®, Bristol-Meyers Squibb, CAS 33069-62-4) or docetaxel (Taxotere®, Sanofi-Aventis, CAS 114977-28-5). It is also contemplated that combinations of semi-synthetic derivatives of a natural taxoid and a JAK2 inhibitor will also enhance cytotoxic therapy. One such example of a semi-synthetic derivative of taxoid is cabazitaxel (Jevtana®, Sanofi-Aventis, CAS 183133-96-2), and an example of a JAK2 inhibitor is SAR302503 (Sanofi-Aventis, CAS 936091-26-8). Other JAK2 inhibitors include, for example, CYT387 (YM BioSciences Inc., CAS 1056634-68-4), SB1518 [pacritinib, S*BIO Pte Ltd. (Singapore, Singapore), CAS 937272-79-2], CEP701 (lestaurtinib, Cephalon, CAS 111358-88-4), and LY2784544 (Eli Lilly and Company, CAS 1229236-86-5). The dose-limiting toxicity of such a combination is expected to be myelosuppression. Other combinations of JAK2 inhibitor therapy for the treatment of cancer contemplated herein, include radiotherapy, and other cancer specific agents, such as an androgen receptor inhibitor or mediator. Illustrative androgen receptor inhibitors include, for example, a steroidal antiandrogen (for example, cyperterone, CAS 2098-66-0); a non-steroidal antiandrogen (for example, flutamide, Eulexin®, Schering-Plough, CAS 13311-84-7); nilutamide (Nilandron®, CAS 63612-50-0); enzalutamide (Xtandi®, Medivation, CAS 915087-33-1); bicalutamide (Casodex®, AstraZeneca, CAS 90357-06-5); a peptide antiandrogen; a small molecule antiandrogen (for example, RU58642 (Roussel-Uclaf SA, CAS 143782-63-2); LG120907 and LG105 (Ligand Pharmaceuticals); RD162 (Medivation, CAS 915087-27-3); BMS-641988 (Bristol-Meyers Squibb, CAS 573738-99-5); and CH5137291 (Chugai Pharmaceutical Co. Ltd., CAS 104344603904)); a natural antiandrogen (for example, ataric acid (CAS 4707-47-5) and N-butylbensensulfonamide (CAS 3622-84-2); a selective androgen receptor modulator for example, enobosarm (Ostarine®, Merck & Company, CAS 841205-47-8); BMS-564,929 (Bristol-Meyer Squibb, CAS 627530-84-1); LGD-4033 (CAS 115910-22-4); AC-262,356 (Acadia Pharmaceuticals); LGD-3303 (Ganolix Lifescience Co., Ltd., 9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo [3,2-f]quinolin-7(6H)-one; S-40503, Kaken Pharmaceuticals, 2-[4-(dimethylamino)-6-nitro-1,2,3,4-tetrahydroquinolin-2-yl]-2-methylpropan-1-ol); andarine (GTx-007, S-4, GTX, Inc., CAS 401900-40-1); and S-23 (GTX, Inc., (2S)-N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide)); or those described in U.S. Patent Appln. No. 2009/0304663.
- Other cancer specific agents or chemotherapeutic agents that may be used in combination with JAK inhibitor therapy include, for example: alkylating agents such as nitrogen mustards such as mechlorethamine (HN2), cyclophosphamide, ifosfamide, melphalan (L-sarcolysin) and chlorambucil; ethylenimines and methylmelamines such as hexamethylmelamine, thiotepa; alkyl sulphonates such as busulfan; nitrosoureas such as carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU) and streptozocin (streptozotocin); and triazenes such as decarbazine (DTIC; dimethyltriazenoimidazole-carboxamide); antimetabolites including folic acid analogues such as methotrexate (amethopterin); pyrimidine analogues such as fluorouracil (5-fluorouracil; 5-FU), floxuridine (fluorodeoxyuridine; FUdR) and cytarabine (cytosine arabinoside); and purine analogues and related inhibitors such as mercaptopurine (6-mercaptopurine; 6-MP), thioguanine (6-thioguanine; TG) and pentostatin (2′-deoxycoformycin); natural products including vinca alkaloids such as vinblastine (VLB) and vincristine; epipodophyllotoxins such as etoposide and teniposide; antibiotics such as dactinomycin (actinomycin D), daunorubicin (daunomycin; rubidomycin), doxorubicin, bleomycin, plicamycin (mithramycin) and mitomycin (mitomycin C); enzymes such as L-asparaginase; biological response modifiers such as interferon alphenomes; other agents such as platinum coordination complexes such as cisplatin (cis-DDP) and carboplatin; anthracenedione such as mitoxantrone and anthracycline; substituted urea such as hydroxyurea; methyl hydrazine derivative such as procarbazine (N-methylhydrazine, MTH); adrenocortical suppressant such as mitotane (o,p′-DDD) and aminoglutethimide; taxol analogues/derivatives; hormone agonists/antagonists such as flutamide and tamoxifen; and GnRH and analogues thereof.
- Applicants further believe that activation of the JAK/STAT pathway is a survival pathway for a proportion of cancers surviving in a subject and that targeting this pathway will result in a toxic insult to the cancer, leading to, for example, inhibiting the growth or proliferation of the cancer, inducing the killing of the cancer, and/or inhibiting or reversing the development or progression of the cancer in a subject. By specifically addressing one or more of the following areas in a collaborative, integrated and multi-disciplinary project, it is contemplated that novel therapies can be developed for this lethal and burdensome disease, and may also provide therapeutic insight into adaptive mechanisms that can be ascertained as operative in malignancies such as tumors and cancer: a) dissect the components of the JAK/STAT pathway that are most relevant to the cancer survival phenotype, b) develop biomarkers for identifying the cancers with this pathway activated and which are thus susceptible to its targeting, c) develop the clinical science of introducing JAK inhibitors to the treatment of the cancer in a subject, and d) develop inhibitor(s) of the JAK/STAT pathway, including selective inhibitors to the most relevant components of the JAK/STAT pathway responsible for the survival phenotype.
- It is further believed that the specifics of JAK/STAT survival pathway signaling are context and disease specific. An observation made in breast cancer that radioresistant aggressive tumors express a transcriptomic signature closely related to interferon signaling, which makes these cells highly resistant to a variety of therapies and enhances their metastatic propensity. Of note, this signature is comprised of genes activated by JAK1/JAK2/STAT1/STAT3 signaling. This activated JAK/STAT pathways are common in multiple clinical and preclinical tumor models, and have been linked to poor prognosis. In prostate cancer, for example, high expression of both pJAK1 and pSTAT3 have been associated with decreased recurrence free survival following both definitive therapy for localized disease as well as androgen deprivation. Furthermore anti-sense inhibition of STAT3 has been suggested to enhance apoptosis in prostate cancer cell lines.
- Surprisingly and unexpectedly, Applicants' results show that the components mediating the survival pathway in prostate cancer are JAK1, JAK2, STAT1 and STAT3. As such and as described more fully below, Applicants' approach includes pharmacological and h/siRNA-based approaches combined with growth/survival assays, biochemical analysis and whole-genome expressional profiling to estimate the relative contribution of JAK1, JAK2, STAT1 and STAT3 on growth and radio/chemoresistance of prostate cancer cells.
- It is also important to elucidate the specific mediators of the survival phenotype of prostate cancer cells with an activated JAK/STAT pathway, since these may provide insight into effective pathway targeting. Applicants have shown that the survival phenotype of castrate resistant cell lines CWRR1 and CW22Rv1 is dependent on MCL1, which is both a STAT1 as well as a STAT3 regulated gene. MCL1 is also an apoptosis inhibitor commonly amplified in various cancers, including prostate cancer. Applicants conclude, therefore, that MCL1 is a mediator of the JAK/STAT dependent survival phenotype and provides not only mechanistic insight, but an additional therapeutic target to prostate cancer.
- The overarching hypothesis addressed is that JAK/STAT signaling is needed for maintaining cancer cell survival in a subset of cancers, including, for example, late stage castrate resistant prostate cancers, particularly in the context of additional toxic insults, and is therefore a therapeutic target. To address this hypothesis in mCRPC, for example, a multi-prong, interdisciplinary, and highly interactive approach was taken with three basic approaches. The first approach identified and elucidated the specifics of the JAK/STAT pathway relevant for the survival phenotype in mCRPC utilizing a combination of genetic and chemical approaches. The second approach develops the clinical science necessary for introducing JAK inhibitors into the therapeutic armamentarium under the hypothesis that effective targeting may include combination strategies. These specific approaches may be carried out simultaneously, but each can and will be modified on the basis of emerging data from the other specific aims. Further, within the first approach, there were 2 subaims: 1) to dissect the relative impact of JAK1 vs. JAK2 and STAT1 vs. STAT3 on JAK/STAT-dependent tumor survival, and 2) to validate MCL1 as a down-stream mediator of JAK/STAT-dependent survival pathways and as a potential additional target for radio/chemosensitization of hormone-resistant prostate cancer; and within the second approach there were three subaims: 1) to conduct in vivo xenograft studies of SAR302503 in combination with various standard prostate cancer treatments, and 2) to conduct a human phase 1 clinical trial of SAR302503 and cabazitaxel in patients with castrate resistant prostate cancer.
- The term “subject” refers to any organism classified as a mammal, including mice, rats, guinea pigs, rabbits, dogs, cats, cows, horses, monkeys, and other mammals. In one preferred embodiment, the subjects are humans.
- As used herein, the term “cancer” refers to a class of diseases of mammals characterized by uncontrolled cellular growth. The term “cancer” is used interchangeably with the terms “tumor,” “solid tumor,” “malignancy,” “hyperproliferation” and “neoplasm.” Cancer includes all types of hyperproliferative growth, hyperplasic growth, neoplastic growth, cancerous growth or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. Illustrative examples include, lung, prostate, head and neck, breast and colorectal cancer, melanomas and gliomas (such as a high grade glioma, including glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adult humans).
- As used herein, the phrase “solid tumor” includes, for example, lung cancer, head and neck cancer, brain cancer, oral cancer, colorectal cancer, breast cancer, prostate cancer, pancreatic cancer, and liver cancer. Other types of solid tumors are named for the particular cells that form them, for example, sarcomas formed from connective tissue cells (for example, bone cartilage, fat), carcinomas formed from epithelial tissue cells (for example, breast, colon, pancreas) and lymphomas formed from lymphatic tissue cells (for example, lymph nodes, spleen, thymus). Treatment of all types of solid tumors regardless of naming convention is within the scope of this invention.
- JAK (Janus Kinase) refers to a family of intracellular, nonreceptor tyrosine kinases. JAK may include four family members, Janus 1 (JAK1), Janus 2 (JAK2), Janus 3 (JAK3), and Tyrosine kinase 2 (Tyk2).
- STAT (Signal Transducer and Activator of Transcription) plays a role in regulating cell growth, survival and differentiation and the family includes STAT1, STAT2,
STAT 3, STAT4, STAT5 (STAT5a and STAT5b), and STATE. - The phrase “JAK/STAT pathway inhibitor,” as used herein, refers to an inhibitor that provides inhibition of the pathway to an extent that can be measured by conventional biochemical techniques.
- Methods and assays for determining the level of JAK inhibition, and for determining whether and to what extent an agent inhibits JAK, are described in, for example, Babon J J, Murphy J M, In vitro JAK kinase activity and inhibition assays, Methods Mol Biol. 2013; 967:39-55.
- Without being bound by theory, Applicants envision that the JAK inhibitor will be therapeutically useful in a subject with a cancer having an activated JAK. The activity of JAK and its family members can be measured directly by kinase assay, or indirectly by staining with commercially available antibodies (including, for example, antibody for total Jak2 sc-294, and antibody for activated (phosphorylated) Jak2 c-21870, Santa Cruz Biotechnology, CA), as is well known to a person skilled in the art.
- Without being bound by theory, Applicants appreciate that JAK inhibitors may not work in a subject with a cancer that express little or no levels of MCL1. Thus, a typical subject is one with cancer that expresses elevated or high levels of MCL1 as compared to a normal non-disease state subject. Based on transcriptional data (see Oncomine: https://www.oncomine.org/resource/main.html) expressional levels of MCL1 mRNA are increased in prostate carcinomas relative to normal prostate tissues at 20-30% in average (see Taylor B S et al., Cancer Cell, 2010, Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010 July 13; 18(1):11-22; Yu Y P, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo J H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004 July 15; 22(14):2790-9.). As more objective measure, increase in the copy numbers of MCL1 gene can be considered, where any significant increase of copy numbers > than 2 per cell can be considered as elevated (see The Cancer Genome Atlas—Prostate Adenocarcinoma DNA Copy Number Data, http://tcga-data.nci.nih.gov/tcga/).
- It is also contemplated that the JAK inhibitor may be, for example, a molecule that binds to the active or inactive conformation of the kinase ATP pocket or a non-ATP competitive kinase inhibitor, and can be a small molecule, a polynucleotide, or encoded by a polynucleotide, for example. Polynucleotides may be administered by any effective method known in the art, for example, parenterally (e.g., intravenously, subcutaneously, intramuscularly) or by oral, nasal or other means that permit the oligonucleotides to access and circulate in the subject's bloodstream. Polynucleotides administered systemically may be given in addition to locally administered polynucleotides, but also have utility in the absence of local administration. A dosage in the range of from about 0.1 to about 10 grams per administration to an adult human will likely be effective for this purpose. The polynucleotide may also be administered as a suitable genetic construct or as nanoparticle (as is described in Costa P M et al., Mol Ther Nucleic Acids. 2013 June 18; 2:e100) and delivered to the subject where it is expressed. Typically, the polynucleotide in the genetic construct is operatively linked to a promoter that can express the compound in the cell. The genetic constructs can be prepared using methods well known in the art, for example, Gil M, Seshadri M, Komorowski M P, Abrams S I, Kozbor D., Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases, Proc Natl Acad Sci USA. 2013 April 2; 110(14):E1291-300.
- The present disclosure also includes the use of an inhibitor of JAK or polynucleotide which encodes an inhibitor of JAK in the preparation of a medicament for the treatment of cancer, including prostate cancer, and in a subject, who may also be administered a further anti-cancer agent. The subject may have been administered the anti-cancer agent previously, or is administered the anti-cancer agent simultaneously with the medicament, or is administered the anti-cancer agent after the medicament.
- The phrases “selective JAK/STAT pathway inhibitor,” or “selective JAK inhibitor,” or “selective STAT inhibitor,” refer to an inhibitor that inhibits a particular member of the JAK or STAT family a greater extent than that of another member of the family. For example, a selective JAK inhibitor may include: 1) an inhibitor that selectively inhibits JAK1 but not JAK2, JAK3, or Tyk2; or 2) an inhibitor that selectively inhibits JAK2 but not JAK1, JAK3, or Tyk2. A selective STAT inhibitor may include, for example: 1) an inhibitor that selectively inhibits STAT 1, but not STAT2,
STAT 3, STAT4, STAT5 (STAT5a and STAT5b), and STAT6; or 2) an inhibitor that selectively inhibitsSTAT 2, but not STAT1,STAT 3, STAT4, STAT5 (STAT5a and STAT5b), and STAT6. Selective inhibition refers to inhibition of the particular family member that is about 2-fold to about 10-fold greater than that of the other family members (that is based on differences in the constants of inhibition). - Suppression of a gene refers to the absence of expression of a gene or a decrease in expression of a gene as compared to the activity of an untreated gene. Suppression of a gene may be determined by detecting the presence or absence of expression of a gene or by measuring a decrease of expression of a gene by any means known in the art including, for example, detecting a decrease in the level of the final gene product, such as a protein, or detecting a decreased level of a precursor, such as mRNA, from which gene expression levels may be inferred when compared to normal gene activity, such as a negative (untreated) control. Any molecular biological assay to detect mRNA or an immunoassay to detect a protein known in the art can be used. A molecular biological assay may include, for example, polymerase chain reaction (PCR), Northern blot, Dot blot, or an analysis method with microarray or macroarray. An immunological assay includes, for example, ELISA (enzyme-linked immunosorbent assay) with a microtiter plate, radioimmunoassay (RIA), a fluorescence antibody technique, Western blotting, or an immune structure dyeing method. Suppression of a gene may also be inferred biologically in vivo, in situ, and/or in vitro, by the suppression of growth or proliferation of a tumor or cancer cell, cell death of a tumor or cancer cell, and/or the sensitization of a tumor or cancer cell to chemotherapy and/or radiotherapy. Illustratively, a therapeutically effective amount of gene suppression in a subject results in the suppression of growth or proliferation of a tumor or cancer cell, cell death of the tumor or cancer cell, and/or the sensitization of the tumor or cancer cell to chemotherapy and/or radiotherapy. As each subject is different and each cancer is different, the amount of gene suppression to achieve a therapeutically effective amount of gene suppression may be determined by a trained professional skilled in the area on a case-by-case basis. Illustratively, a therapeutically effective amount of gene suppression may include, for example, less than or equal to about 95% of normal gene activity, or less than or equal to about 90% of normal gene activity, or less than or equal to about 85% of normal gene activity, or less than or equal to about 80% of normal gene activity, or less than or equal to about 75% of normal gene activity, or less than or equal to about 65% of normal gene activity, or less than or equal to about 50% of normal gene activity, or less than or equal to about 35% of normal gene activity, or less than or equal to about 25% of normal gene activity, or less than or equal to about 15% of normal gene activity, or less than or equal to about 10% of normal gene activity, or less than or equal to about 7.5% of normal gene activity, or less than or equal to about 5% of normal gene activity, or less than or equal to about 2.5% of normal gene activity, or less than or equal to about 1% of normal gene activity, or less than or equal to about 0% of normal gene activity.
- Suppression of identified genes individually or in combination with ionizing radiation and/or any chemotherapeutic agents may improve the outcome of patients treated with the ionizing radiation or any chemotherapy agent or any treatment designed to improve outcome of the cancer patients (like JAK1/JAK2 inhibitors) if such treatment is combined with the suppression of any of these genes or their combination.
- Radiotherapy is based on ionizing radiation delivered to a target area that results in death of reproductive tumor cells. Some examples of radiotherapy include the radiation of cesium, palladium, iridium, iodine, or cobalt radiotherapy which is usually delivered as ionizing radiation from a linear accelerator or an isotopic source such as a cobalt source. Also variations on linear accelerators are Cyberkine and Tomotherapy. Particle radiotherapy from cyclotrons such as Protons or Carbon nuclei may be employed. Also radioisotopes delivered systemically such as p32 or radium 223 may be used. The external radiotherapy may be systemic radiation in the form of sterotacktic radiotherapy total nodal radiotherapy or whole body radiotherapy but is more likely focused to a particular site, such as the location of the tumor or the solid cancer tissues (for example, abdomen, lung, liver, lymph nodes, head, etc.). The radiation dosage regimen is generally defined in terms of Gray or Sieverts time and fractionation, and must be carefully defined by the radiation oncologist. The amount of radiation a subject receives will depend on various considerations. The two important considerations are the location of the tumor in relation to other critical structures or organs of the body, and the extent to which the tumor has spread. One illustrative course of treatment for a subject undergoing radiation therapy is a treatment schedule over a 5 to 8 week period, with a total dose of 50 to 80 Gray (Gy) administered to the subject in a single daily fraction of 1.8 to 2.0 Gy, 5 days a week. A Gy is an abbreviation for Gray and refers to 100 rad of dose.
- Radiotherapy can also include implanting radioactive seeds inside or next to an site designated for radiotherapy and is termed brachytherapy (or internal radiotherapy, endocurietherapy or sealed source therapy). For prostate cancer, there are currently two types of brachytherapy: permanent and temporary. In permanent brachytherapy, radioactive (iodine-125 or palladium-103) seeds are implanted into the prostate gland using an ultrasound for guidance. Illustratively, about 40 to 100 seeds are implanted and the number and placement are generally determined by a computer-generated treatment plan known in the art specific for each subject. Temporary brachytherapy uses a hollow sources placed into the prostate gland that is filled with radioactive material (iridium-192) for about 5 to about 15 minutes, for example. Following treatment, the needle and radioactive material are removed. This procedure is repeated two to three times over a course of several days.
- Radiotherapy can also include radiation delivered by external beam radiation therapy (EBRT), including, for example, a linear accelerator (a type of high-powered X-ray machine that produces very powerful photons that penetrate deep into the body); proton beam therapy where photons are derived from a radioactive source such as iridium-192, caesium-137, radium-226 (no longer used clinically), or colbalt-60; Hadron therapy; multi-leaf collimator (MLC); and intensity modulated radiation therapy (IMRT). During this type of therapy, a brief exposure to the radiation is given for a duration of several minutes, and treatment is typically given once per day, 5 days per week, for about 5 to 8 weeks. No radiation remains in the subject after treatment. There are several ways to deliver EBRT, including, for example, three-dimensional conformal radiation therapy where the beam intensity of each beam is determined by the shape of the tumor. Illustrative dosages used for photon based radiation is measured in Gy, and in an otherwise healthy subject (that is, little or no other disease states present such as high blood pressure, infection, diabetes, etc.) for a solid epithelial tumor ranges from about 60 to about 80 Gy, and for a lymphoma ranges from about 20 to about 40 Gy. Illustrative preventative (adjuvant) doses are typically given at about 45 to about 60 Gy in about 1.8 to about 2 Gy fractions for breast, head, and neck cancers.
- When radiation therapy is a local modality, radiation therapy as a single course of therapy is unlikely to provide a cure for those tumors that have metastasized distantly outside the zone of treatment. Thus, the use of radiation therapy with other modality regimens, including chemotherapy, have important beneficial effects for the treatment of metastasized cancers.
- Radiation therapy has also been combined temporally with chemotherapy to improve the outcome of treatment. There are various terms to describe the temporal relationship of administering radiation therapy and chemotherapy, and the following examples are illustrative treatment regimens and are generally known by those skilled in the art and are provided for illustration only and are not intended to limit the use of other combinations. “Sequential” radiation therapy and chemotherapy refers to the administration of chemotherapy and radiation therapy separately in time in order to allow the separate administration of either chemotherapy or radiation therapy. “Concomitant” radiation therapy and chemotherapy refers to the administration of chemotherapy and radiation therapy on the same day. Finally, “alternating” radiation therapy and chemotherapy refers to the administration of radiation therapy on the days in which chemotherapy would not have been administered if it was given alone.
- It should be noted that other therapeutically effective doses of radiotherapy can be determined by a radiation oncologist skilled in the art and can be based on, for example, whether the subject is receiving chemotherapy, if the radiation is given before or after surgery, the type and/or stage of cancer, the location of the tumor, and the age, weight and general health of the subject.
- Based on the functional groups, we also contemplate that suppression of the chemokine signaling, or suppression of negative regulators of interferon response, or suppression of protein degradation or mitochondria-related anti-apoptotic molecules or anti-viral proteins or extracellular matrix proteins (ECM) alone or in combination with ionizing radiation or any chemotherapy drug or any treatment designed to improve outcome of the cancer patients will improve cancer treatment. This is based on the functional associations between detected targets. DHX58 (also known as LGP2) is known as an apical suppressor of RNA dependent activation of the Type I interferons alpha and beta. IFITM1 and OASL are known anti-viral proteins. USP18 and HERC5 are enzymes involved in protein ISGylation/de-ISGylation, known to protect proteins from ubiquitin-dependent degradation in proteosome complex, while PSMB9 and PSMB10 are proteasome subunits. EPSTL1, LGALS3P and TAGLN are involved in the structure and functional regulation of ECM. CXCL9 and CCL2 are chemokines with multiple functions including growth-promoting functions for tumor cells.
- As used herein, the term “chemoresistant” refers to a tumor or cancer cell that shows little or no significant detectable therapeutic response to an agent used in chemotherapy.
- As used herein, the term “radioresistant” refers to a tumor or cancer cell that shows little or no significant detectable therapeutic response to an agent used in radiotherapy such as ionizing radiation.
- As used herein, the term “chemosensitive” refers to a tumor or cancer cell that shows a detectable therapeutic response to an agent used in chemotherapy.
- As used herein, the term “radiosensitive” refers to a tumor or cancer cell that shows a detectable therapeutic response to an agent used in radiotherapy.
- As used herein, the phrases “chemotherapeutic agent,” “cytotoxic agent,” “anticancer agent,” and “antitumor agent” are used interchangeably and refer to an agent that has the effect of inhibiting the growth or proliferation, or inducing the killing, of a tumor or cancer cell. The chemotherapeutic agent may inhibit or reverse the development or progression of a tumor or cancer, such as for example, a solid tumor.
- As used herein, the term “chemotherapy” refers to administration of at least one chemotherapeutic agent to a subject having a tumor or cancer.
- As used herein, the term “radiotherapy” refers to administration of at least one “radiotherapeutic agent” to a subject having a tumor or cancer and refers to any manner of treatment of a tumor or cancer with a radiotherapeutic agent. A radiotherapeutic agent includes, for example, ionizing radiation including, for example, external beam radiotherapy, stereotatic radiotherapy, virtual simulation, 3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, ionizing particle therapy and radioisotope therapy.
- The term “taxoid,” as used herein, refers to a class of derivatives from taxol, which were developed for their anti-cancer properties. Taxoids are similar to taxanes. Taxoids may include taxotere.
- The term “paclitaxel,” as used herein, refers to a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel.
- Paclitaxel may be used to treat patients with lung, ovarian, breast, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel may be also used for the prevention of restenosis.
- Paclitaxel stabilizes microtubules and, as a result, interferes with the normal breakdown of microtubules during cell division. Together with docetaxel, it forms the drug category of the taxanes.
- The term “Docetaxel,” as used herein, refers to a clinically well-established anti-mitotic chemotherapy medication that works by interfering with cell division. Docetaxel is as generic or under the trade name Taxotere or Docecad. Docetaxel is approved by the FDA for treatment of locally advanced or metastatic breast cancer, head and neck cancer, gastric cancer, hormone-refractory prostate cancer and non small-cell lung cancer. Docetaxel can be used as a single agent or in combination with other chemotherapeutic drugs as indicated depending on specific cancer type and stage.
- Docetaxel is a member of the taxane drug class, which also includes the chemotherapeutic medication paclitaxel. Although docetaxel remains twice as potent as paclitaxel (due to docetaxel's effect on the centrosome of the mitotic spindle), the two taxanes have been observed to have comparable efficacy.
- The term “cabazitaxel,” previously “XRP-6258,” or trade name “Jevtana,” as used herein, refers to a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on Jun. 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
- Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
- The term “antiandrogen” or “androgen antagonists,” as used herein, refers to any compound or substance which can prevent androgens from expressing their biological effects on responsive tissues. Antiandrogens may alter the androgen pathway by blocking the appropriate receptors, competing for binding sites on the cell's surface, or affecting androgen production. Antiandrogens can be prescribed to treat an array of diseases and disorders. In men, antiandrogens are most frequently used to treat prostate cancer. In women, antiandrogens are used to decrease levels of male hormones causing symptoms of hyperandrogenism. Antiandrogens present in the environment have become a topic of concern. Many industrial chemicals, pesticides and insecticides exhibit antiandrogenic effects. Certain plant species have also been found to produce antiandrogens. Environmental antiandrogens can have harmful effects on reproductive organ development in fetuses exposed in utero as well as their offspring.
- The phrase “combination therapy” (or “co-therapy”) embraces the administration of an agent used in JAK/STAT pathway inhibition and one or more of anticancer agents such as a chemotherapeutic agent and/or radiation therapy, as part of a specific treatment regimen intended to provide a beneficial effect from the co-action of the JAK/STAT pathway inhibitor and the other agent. The beneficial effect of the combination may include, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination. Administration of the combination typically is carried out over a defined time period (usually minutes, hours, days or weeks depending upon the combination selected). “Combination therapy” generally is not intended to encompass the administration of an agent as part of separate monotherapy regimens that incidentally and arbitrarily result in the combinations of the present invention. “Combination therapy” is intended to embrace administration of the agents in a sequential manner, that is, wherein the agents are administered at different times, as well as administration of the agents in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject concurrently with radiation therapy a single capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules for each therapeutic agent. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents, if more than one, can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection. The sequence in which the agents are administered is not narrowly critical although radiation therapy typically will follow the administration of the JAK2 inhibitor. “Combination therapy” can also embrace the administration of the agents as described above in further combination with other biologically active ingredients (such as, but not limited to, an antineoplastic agent) and non-drug therapies (such as, but not limited to, surgery). The radiation treatment of the combination may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the agents is achieved. For example, in appropriate cases, the beneficial effect is still achieved even when the radiation treatment is temporally removed from the administration of the other agent, perhaps by days or even weeks.
- An illustrative antineoplastic agent or chemotherapeutic agent may include, for example, a standard taxane. Taxanes are produced by the plants of the genus Taxus and are classified as diterpenes and widely uses as chemotherapy agents including, for example, paclitaxel, (Taxol®, Bristol-Meyers Squibb, CAS 33069-62-4) and docetaxel (Taxotere®, Sanofi-Aventis, CAS 114977-28-5). Other chemotherapeutic agent may include semi-synthetic derivatives of a natural taxoid such as cabazitaxel (Jevtana®, Sanofi-Aventis, CAS 183133-96-2). Other chemotherapeutic agent may also include an androgen receptor inhibitor or mediator. Illustrative androgen receptor inhibitors may include, a steroidal antiandrogen (for example, cyperterone, CAS 2098-66-0); a non-steroidal antiandrogen (for example, flutamide, Eulexin®, Schering-Plough, CAS 13311-84-7); nilutamide (Nilandron®, CAS 63612-50-0); enzalutamide (Xtandi®, Medivation®, CAS 915087-33-1); bicalutamide (Casodex, AstraZeneca, CAS 90357-06-5); a peptide antiandrogen; a small molecule antiandrogen (for example, RU58642 (Roussel-Uclaf SA, CAS 143782-63-2); LG120907 and LG105 (Ligand Pharmaceuticals); RD162 (Medivation, CAS 915087-27-3); BMS-641988 (Bristol-Meyers Squibb, CAS 573738-99-5); and CH5137291 (Chugai Pharmaceutical Co. Ltd., CAS 104344603904)); a natural antiandrogen (for example, ataric acid (CAS 4707-47-5) and N-butylbensensulfonamide (CAS 3622-84-2); a selective androgen receptor modulator (for example, enobosarm (Ostarine®, Merck & Company, CAS 841205-47-8); BMS-564,929 (Bristol-Meyer Squibb, CAS 627530-84-1); LGD-4033 (CAS 115910-22-4); AC-262,356 (Acadia Pharmaceuticals); LGD-3303 (Ganolix Lifescience Co., Ltd., 9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo [3,2-f]quinolin-7(6H)-one; 5-40503, Kaken Pharmaceuticals, 2-[4-(dimethylamino)-6-nitro-1,2,3,4-tetrahydroquinolin-2-yl]-2-methylpropan-1-ol); andarine (GTx-007, S-4, GTX, Inc., CAS 401900-40-1); and S-23 (GTX, Inc., (2S)-N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide)); or those described in U.S. Patent Appln. No. 2009/0304663. Other neoplastic agents or chemotherapeutic agents that can be used may include, for example: alkylating agents such as nitrogen mustards such as mechlorethamine (HN2), cyclophosphamide, ifosfamide, melphalan (L-sarcolysin) and chlorambucil; ethylenimines and methylmelamines such as hexamethylmelamine, thiotepa; alkyl sulphonates such as busulfan; nitrosoureas such as carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU) and streptozocin (streptozotocin); and triazenes such as decarbazine (DTIC; dimethyltriazenoimidazole-carboxamide); antimetabolites including folic acid analogues such as methotrexate (amethopterin); pyrimidine analogues such as fluorouracil (5-fluorouracil; 5-FU), floxuridine (fluorodeoxyuridine; FUdR) and cytarabine (cytosine arabinoside); and purine analogues and related inhibitors such as mercaptopurine (6-mercaptopurine; 6-MP), thioguanine (6-thioguanine; TG) and pentostatin (2′-deoxycoformycin); natural products including vinca alkaloids such as vinblastine (VLB) and vincristine; epipodophyllotoxins such as etoposide and teniposide; antibiotics such as dactinomycin (actinomycin D), daunorubicin (daunomycin; rubidomycin), doxorubicin, bleomycin, plicamycin (mithramycin) and mitomycin (mitomycin C); enzymes such as L-asparaginase; biological response modifiers such as interferon alphenomes; other agents such as platinum coordination complexes such as cisplatin (cis-DDP) and carboplatin; anthracenedione such as mitoxantrone and anthracycline; substituted urea such as hydroxyurea; methyl hydrazine derivative such as procarbazine (N-methylhydrazine, MTH); adrenocortical suppressant such as mitotane (o,p′-DDD) and aminoglutethimide; taxol analogues/derivatives; hormone agonists/antagonists such as flutamide and tamoxifen; and GnRH and analogues thereof. Examples of other chemotherapeutic can be found in Cancer Principles and Practice of Oncology by V. T. Devita and S. Hellman (editors), 6.sup.th edition (Feb. 15, 2001), Lippincott Williams & Wilkins Publishers.
- Compositions herein may be formulated for oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal, injection/injectable, and/or parental (including subcutaneous, intramuscular, intravenous, and intradermal) administration. Other suitable administration routes are incorporated herein. The compositions may be presented conveniently in unit dosage forms and may be prepared by any methods known in the pharmaceutical arts. Examples of suitable drug formulations and/or forms are discussed in, for example, Hoover, John E. Remington's Pharmaceutical Sciences, Mack Publishing Co., Eston, Pa.; 18.sup.th edition (1995); and Liberman, H. A. and Lachman, L. Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980. Illustrative methods may include the step of bringing one or more active ingredients into association with a carrier that constitutes one or more accessory ingredients. In general, the compositions may be prepared by bringing into association uniformly and intimately one or more active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
- Pharmaceutical formulations may include those suitable for oral, intramuscular, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. One or more of the compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- A salt may be a pharmaceutically suitable (i.e., pharmaceutically acceptable) salt including, but not limited to, acid addition salts formed by mixing a solution of the instant compound with a solution of a pharmaceutically acceptable acid. A pharmaceutically acceptable acid may be, for example, hydrochloric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- Suitable pharmaceutically-acceptable salts may further include, but are not limited to salts of pharmaceutically-acceptable inorganic acids, including, for example, sulfuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically-acceptable organic acids such propionic, butyric, maleic, hydroxymaleic, lactic, mucic, gluconic, benzoic, succinic, phenylacetic, toluenesulfonic, benezenesulfonic, salicyclic sulfanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic, and valeric acids.
- Various pharmaceutically acceptable salts may include, for example, the list of FDA-approved commercially marketed salts including acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, mitrate, pamoate, pantothenate, phosphate, diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, and triethiodide.
- A hydrate may be a pharmaceutically suitable (i.e., pharmaceutically acceptable) hydrate that is a compound formed by the addition of water or its elements to a host molecule (for example, the free form version of the compound) including, but not limited to, monohydrates, dihydrates, etc. A solvate may be a pharmaceutically suitable (i.e., pharmaceutically acceptable) solvate, whereby solvation is an interaction of a solute with a solvent which leads to stabilization of the solute species in a solution, and whereby the solvated state is an ion in a solution complexed by solvent molecules. Solvates and hydrates may also be referred to as “analogues.”
- A prodrug may be a compound that is pharmacologically inert but is converted by enzyme or chemical action to an active form of the drug (i.e., an active pharmaceutical ingredient) at or near the predetermined target site. In other words, prodrugs are inactive compounds or partially active compounds that yield an active compound upon metabolism in the body, which may or may not be enzymatically controlled. Prodrugs may also be broadly classified into two groups: bioprecursor and carrier prodrugs. Prodrugs may also be subclassified according to the nature of their action. Bioprecursor prodrugs are compounds that already contain the embryo of the active species within their structure, whereby the active species are produced upon metabolism.
- Carrier prodrugs are formed by combining the active drug (e.g., active ingredient) with a carrier species forming a compound having desirable chemical and biological characteristics, whereby the link is an ester or amide so that the carrier prodrug is easily metabolized upon absorption or delivery to the target site. For example, lipophilic moieties may be incorporated to improve transport through membranes. Carrier prodrugs linked by a functional group to carrier are referred to as bipartite prodrugs. Prodrugs where the carrier is linked to the drug by a separate structure are referred to as tripartite prodrugs, whereby the carrier is removed by an enzyme-controlled metabolic process, and whereby the linking structure is removed by an enzyme system or by a chemical reaction. A hydroxy-protecting group includes, for example, a tert-butyloxy-carbonyl (t-BOC) and t-butyl-dimethyl-silyl (TBS). Other hydroxy protecting groups contemplated are known in the art.
- In another embodiment, a dosage form and/or composition may include one or more active metabolites of the active ingredients in place of or in addition to the active ingredients disclosed herein.
- Dosage form compositions containing the active ingredients may also contain one or more inactive pharmaceutical ingredients such as diluents, solubilizers, alcohols, binders, controlled release polymers, enteric polymers, disintegrants, excipients, colorants, flavorants, sweeteners, antioxidants, preservatives, pigments, additives, fillers, suspension agents, surfactants (for example, anionic, cationic, amphoteric and nonionic), and the like. Various FDA-approved topical inactive ingredients are found at the FDA's “The Inactive Ingredients Database” that contains inactive ingredients specifically intended as such by the manufacturer, whereby inactive ingredients can also be considered active ingredients under certain circumstances, according to the definition of an active ingredient given in 21 CFR 210.3(b)(7). Alcohol is a good example of an ingredient that may be considered either active or inactive depending on the product formulation.
- As used herein, an oral dosage form may include capsules (a solid oral dosage form consisting of a shell and a filling, whereby the shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band and whereby capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed), capsule or coated pellets (solid dosage form in which the drug is enclosed within either a hard or soft soluble container or “shell” made from a suitable form of gelatin; the drug itself is in the form of granules to which varying amounts of coating have been applied), capsule coated extended release (a solid dosage form in which the drug is enclosed within either a hard or soft soluble container or “shell” made from a suitable form of gelatin; additionally, the capsule is covered in a designated coating, and which releases a drug or drugs in such a manner to allow at least a reduction in dosing frequency as compared to that drug or drugs presented as a conventional dosage form), capsule delayed release (a solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) at a time other than promptly after administration, whereby enteric-coated articles are delayed release dosage forms), capsule delayed release pellets (solid dosage form in which the drug is enclosed within either a hard or soft soluble container or “shell” made from a suitable form of gelatin); the drug itself is in the form of granules to which enteric coating has been applied, thus delaying release of the drug until its passage into the intestines), capsule extended release (a solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug or drugs in such a manner to allow a reduction in dosing frequency as compared to that drug or drugs presented as a conventional dosage form), capsule film-coated extended release (a solid dosage form in which the drug is enclosed within either a hard or soft soluble container or “shell” made from a suitable form of gelatin; additionally, the capsule is covered in a designated film coating, and which releases a drug or drugs in such a manner to allow at least a reduction in dosing frequency as compared to that drug or drugs presented as a conventional dosage form), capsule gelatin coated (a solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin; through a banding process, the capsule is coated with additional layers of gelatin so as to form a complete seal), and capsule liquid filled (a solid dosage form in which the drug is enclosed within a soluble, gelatin shell which is plasticized by the addition of a polyol, such as sorbitol or glycerin, and is therefore of a somewhat thicker consistency than that of a hard shell capsule; typically, the active ingredients are dissolved or suspended in a liquid vehicle).
- Oral dosage forms contemplated herein also include granules (a small particle or grain), pellet (a small sterile solid mass consisting of a highly purified drug, with or without excipients, made by the formation of granules, or by compression and molding), pellets coated extended release (a solid dosage form in which the drug itself is in the form of granules to which varying amounts of coating have been applied, and which releases a drug or drugs in such a manner to allow a reduction in dosing frequency as compared to that drug or drugs presented as a conventional dosage form), pill (a small, round solid dosage form containing a medicinal agent intended for oral administration), powder (an intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use), elixir (a clear, pleasantly flavored, sweetened hydroalcoholic liquid containing dissolved medicinal agents; it is intended for oral use), chewing gum (a sweetened and flavored insoluble plastic material of various shapes which when chewed, releases a drug substance into the oral cavity), or syrup (an oral solution containing high concentrations of sucrose or other sugars; the term has also been used to include any other liquid dosage form prepared in a sweet and viscid vehicle, including oral suspensions).
- Oral dosage forms contemplated herein may further include a tablet (a solid dosage form containing medicinal substances with or without suitable diluents), tablet chewable (a solid dosage form containing medicinal substances with or without suitable diluents that is intended to be chewed, producing a pleasant tasting residue in the oral cavity that is easily swallowed and does not leave a bitter or unpleasant after-taste), tablet coated (a solid dosage form that contains medicinal substances with or without suitable diluents and is covered with a designated coating), tablet coated particles (a solid dosage form containing a conglomerate of medicinal particles that have each been covered with a coating), tablet delayed release (a solid dosage form which releases a drug or drugs at a time other than promptly after administration, whereby enteric-coated articles are delayed release dosage forms), tablet delayed release particles (a solid dosage form containing a conglomerate of medicinal particles that have been covered with a coating which releases a drug or drugs at a time other than promptly after administration, whereby enteric-coated articles are delayed release dosage forms), tablet dispersible (a tablet that, prior to administration, is intended to be placed in liquid, where its contents will be distributed evenly throughout that liquid, whereby term “tablet, dispersible’ is no longer used for approved drug products, and it has been replaced by the term ‘tablet, for suspension’), tablet effervescent (a solid dosage form containing mixtures of acids, for example, citric acid, tartaric acid, and sodium bicarbonate, which release carbon dioxide when dissolved in water, whereby it is intended to be dissolved or dispersed in water before administration), tablet extended release (a solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form), tablet film coated (a solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer), tablet film coated extended release (a solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer; the tablet is formulated in such manner as to make the contained medicament available over an extended period of time following ingestion), tablet for solution (a tablet that forms a solution when placed in a liquid), tablet for suspension (a tablet that forms a suspension when placed in a liquid, which is formerly referred to as a ‘dispersible tablet’), tablet multilayer (a solid dosage form containing medicinal substances that have been compressed to form a multiple-layered tablet or a tablet-within-a-tablet, the inner tablet being the core and the outer portion being the shell), tablet multilayer extended release (a solid dosage form containing medicinal substances that have been compressed to form a multiple-layered tablet or a tablet-within-a-tablet, the inner tablet being the core and the outer portion being the shell, which, additionally, is covered in a designated coating; the tablet is formulated in such manner as to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form), tablet orally disintegrating (a solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue), tablet orally disintegrating delayed release (a solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue, but which releases a drug or drugs at a time other than promptly after administration), tablet soluble (a solid dosage form that contains medicinal substances with or without suitable diluents and possesses the ability to dissolve in fluids), tablet sugar coated (a solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a colored or an uncolored water-soluble sugar), and the like.
- Injection and infusion dosage forms (i.e., parenteral dosage forms) include, but are not limited to, the following. Liposomal injection includes or forms liposomes or a lipid bilayer vesicle having phospholipids that encapsulate an active drug substance. Injection includes a sterile preparation intended for parenteral use. Five distinct classes of injections exist as defined by the USP. Emulsion injection includes an emulsion comprising a sterile, pyrogen-free preparation intended to be administered parenterally. Lipid complex and powder for solution injection are sterile preparations intended for reconstitution to form a solution for parenteral use.
- Powder for suspension injection is a sterile preparation intended for reconstitution to form a suspension for parenteral use. Powder lyophilized for liposomal suspension injection is a sterile freeze dried preparation intended for reconstitution for parenteral use that is formulated in a manner allowing incorporation of liposomes, such as a lipid bilayer vesicle having phospholipids used to encapsulate an active drug substance within a lipid bilayer or in an aqueous space, whereby the formulation may be formed upon reconstitution. Powder lyophilized for solution injection is a dosage form intended for the solution prepared by lyophilization (“freeze drying”), whereby the process involves removing water from products in a frozen state at extremely low pressures, and whereby subsequent addition of liquid creates a solution that conforms in all respects to the requirements for injections. Powder lyophilized for suspension injection is a liquid preparation intended for parenteral use that contains solids suspended in a suitable fluid medium, and it conforms in all respects to the requirements for Sterile Suspensions, whereby the medicinal agents intended for the suspension are prepared by lyophilization.
- Solution injection involves a liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection. Solution concentrate injection involves a sterile preparation for parenteral use that, upon addition of suitable solvents, yields a solution suitable for injections. Suspension injection involves a liquid preparation (suitable for injection) containing solid particles dispersed throughout a liquid phase, whereby the particles are insoluble, and whereby an oil phase is dispersed throughout an aqueous phase or vice-versa. Suspension liposomal injection is a liquid preparation (suitable for injection) having an oil phase dispersed throughout an aqueous phase in such a manner that liposomes (a lipid bilayer vesicle usually containing phospholipids used to encapsulate an active drug substance either within a lipid bilayer or in an aqueous space) are formed. Suspension sonicated injection is a liquid preparation (suitable for injection) containing solid particles dispersed throughout a liquid phase, whereby the particles are insoluble. In addition, the product may be sonicated as a gas is bubbled through the suspension resulting in the formation of microspheres by the solid particles.
- A parenteral carrier system may include one or more pharmaceutically suitable excipients, such as solvents and co-solvents, solubilizing agents, wetting agents, suspending agents, thickening agents, emulsifying agents, chelating agents, buffers, pH adjusters, antioxidants, reducing agents, antimicrobial preservatives, bulking agents, protectants, tonicity adjusters, and special additives.
- Inhalation dosage forms may include, but are not limited to, aerosol being a product that is packaged under pressure and contains therapeutically active ingredients that are released upon activation of an appropriate valve system intended for topical application to the skin as well as local application into the nose (nasal aerosols), mouth (lingual and sublingual aerosols), or lungs (inhalation aerosols). Inhalation dosage forms further include foam aerosol being a dosage form containing one or more active ingredients, surfactants, aqueous or nonaqueous liquids, and the propellants, whereby if the propellant is in the internal (discontinuous) phase (i.e., of the oil-in-water type), a stable foam is discharged, and if the propellant is in the external (continuous) phase (i.e., of the water-in-oil type), a spray or a quick-breaking foam is discharged. Inhalation dosage forms may also include metered aerosol being a pressurized dosage form consisting of metered dose valves which allow for the delivery of a uniform quantity of spray upon each activation; powder aerosol being a product that is packaged under pressure and contains therapeutically active ingredients, in the form of a powder, that are released upon activation of an appropriate valve system; and aerosol spray being an aerosol product which utilizes a compressed gas as the propellant to provide the force necessary to expel the product as a wet spray and being applicable to solutions of medicinal agents in aqueous solvents.
- Pharmaceutically suitable inhalation carrier systems may include pharmaceutically suitable inactive ingredients known in the art for use in various inhalation dosage forms, such as (but not limited to) aerosol propellants (for example, hydrofluoroalkane propellants), surfactants, additives, suspension agents, solvents, stabilizers and the like.
- A transdermal dosage form may include, but not limited to, a patch being a drug delivery system that often contains an adhesive backing that is usually applied to an external site on the body, whereby the ingredients either passively diffuse from, or are actively transported from some portion of the patch, and whereby depending upon the patch, the ingredients are either delivered to the outer surface of the body or into the body; and other various types of transdermal patches such as matrix, reservoir and others known in the art. The “pharmaceutically suitable transdermal carrier system” may include pharmaceutically suitable inactive ingredients known in the art for use in various transdermal dosage forms, such as (but not limited to) solvents, adhesives, diluents, additives, permeation enhancing agents, surfactants, emulsifiers, liposomes, and the like.
- Suitable dosage amounts and dosing regimens may be selected in accordance with a variety of factors, including one or more particular conditions being treated, the severity of the one or more conditions, the genetic profile, age, health, sex, diet, and weight of the subject, the route of administration alone or in combination with pharmacological considerations including the activity, efficacy, bioavailability, pharmacokinetic, and toxicological profiles of the particular compound employed, whether a drug delivery system is utilized and whether the drug is administered as part of a drug combination. Therefore, the dosage regimen to be employed may vary widely and may necessarily deviate from the dosage regimens set forth herein.
- Contemplated dosage forms may include an amount of one or more JAK/STAT pathway inhibitors ranging from about 1 to about 1200 mg, or about 5 to about 100 mg, or about 25 to about 800 mg, or about 100 to about 500 mg, or 0.1 to 50 milligrams (±10%), or 10 to 100 milligrams (±10%), or 5 to 500 milligrams (±10%), or 0.1 to 200 milligrams (±10%), or 1 to 100 milligrams (±10%), or 5 to 50 milligrams (±10%), or 30 milligrams (+10%), or 20 milligrams (±10%), or 10 milligrams (±10%), or 5 milligrams (±10%), per dosage form, such as, for example, a tablet, a pill, a bolus, and the like.
- In another embodiment, a dosage form may be administered to a subject in need thereof once per day, or twice per day, or once every 6 hours, or once every 4 hours, or once every 2 hours, or hourly, or twice an hour, or twice a day, or twice a week, or monthly.
- The phrase “therapeutically effective” is intended to qualify the amount that will achieve the goal of improvement in disease severity and/or the frequency of incidence over non-treatment, while limiting, reducing, or avoiding adverse side effects typically associated with disease therapies. A “therapeutic effective” amount relieves to some extent one or more of the symptoms of a cancer disease or disorder. In reference to the treatment of a cancer, a therapeutic effect refers to one or more of the following: 1) reduction in the number of cancer cells by, for example, killing the cancer cells; 2) reduction in tumor size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cancer cell infiltration into peripheral organs; 4) inhibition (i.e., slowing to some extent, preferably stopping) of tumor metastasis; 5) inhibition, to some extent, of tumor growth; 6) relieving or reducing to some extent one or more of the symptoms associated with the disorder; and/or 7) relieving or reducing the side effects associated with the administration of anticancer agents. “Therapeutic effective amount” is intended to qualify the amount required to achieve a therapeutic effect.
- A therapeutically effective amount of a JAK/STAT pathway inhibitor may be any amount that begins to improve cancer treatment in a subject either administered alone or in combination with another therapeutic agent. In one embodiment, an effective amount of an inhibitor used in the therapeutic regime described herein may be, for example, about 1 mg, or about 5 mg, or about 10 mg, or about 25 mg, or about 50 mg, or about 100 mg, or about 200 mg, or about 400 mg, or about 500 mg, or about 600 mg, or about 1000 mg, or about 1200 mg, or about 1400 mg, or from about 10 to about 60 mg, or about 50 mg to about 200 mg, or about 150 mg to about 600 mg per day. Further, another effective amount of an inhibitor used herein may be that which results in a detectable blood level of above about 1 ng/dL, 5, ng/dL, 10 ng/dL, 20, ng/dL, 35 ng/dL, or about 70 ng/dL, or about 140 ng/dL, or about 280 ng/dL, or about 350 ng/dL, or lower or higher.
- The term “pharmaceutically acceptable” is used herein to mean that the modified noun is appropriate for use in a pharmaceutical product. Pharmaceutically acceptable cations include metallic ions and organic ions. Other metallic ions may include, but are not limited to appropriate alkali metal salts, alkaline earth metal salts and other physiological acceptable metal ions. Exemplary ions may include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc in their usual valences. Organic ions may include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Pharmaceutically acceptable acids may include without limitation hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.
- It is further contemplated that one active ingredient may be in an extended release form, while an optional second, third, or fourth other active ingredient, for example, may or may not be, so the recipient experiences, for example, a spike in the second, third, or fourth active ingredient that dissipates rapidly, while the first active ingredient is maintained in a higher concentration in the blood stream over a longer period of time. Similarly, one of the active ingredients may be an active metabolite, while another may be in an unmetabolized state, such that the active metabolite has an immediate effect upon administration to a subject whereas the unmetabolized active ingredient administered in a single dosage form may need to be metabolized before taking effect in the subject.
- Also contemplated are solid form preparations that include at least one active ingredient which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms may include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. Solutions or suspensions may be applied topically and/or directly to the nasal cavity, respiratory tract, eye, or ear by conventional means, for example with a dropper, pipette or spray.
- Alternatively, one or more of the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier may form a gel in the nasal cavity. The powder composition may be presented in unit dose form, for example, in capsules or cartridges of, for example, gelatin, or blister packs from which the powder may be administered by means of an inhaler.
- The pharmaceutical preparations may be in unit dosage forms. In such form, the preparation may be subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, such as a kit or other form, the package containing discrete quantities of preparation, such as packeted tablets, capsules, liquids or powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge, or it can be the appropriate number of any of these in packaged form.
- The present disclosure is further illustrated by the following examples, which should not be construed as limiting in any way. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of pharmacology and pharmaceutics, which are within the skill of the art.
- Cell Culture and Growth Assays
- Cell lines were from the American Type Culture Collection (Rockville, Md.), except for CWR-R1 and CWR-22RV1 cells, which were kindly provided by Dr. Donald VanderGriend, the University of Chicago.
- These cell lines were characterized for relative radioresistance using a clonogenic assay. Briefly, the cells were cultured in their appropriate media at 5% CO2 at 37° C. Optimal cell plating concentrations for a p60 dish were determined for each cell line. The majority of cell lines were plated in triplicate at concentrations of 100 cells/plate for control, 1000 cells/plate for 2 Gy, 2000 cells/plate for 5 Gy, and 3000 cells/plate for 8 Gy. Plates were irradiated 24 hours after plating with either 2, 5, or 8 Gy using a irradiated using a Nordion Gammacell 60Co irradiator operating at a dose rate of ˜18 Gy/minute. Cells were allowed to grow for 10-21 days (depending on the cell line) until colonies were >50 cells. Plates were then fixed with formalin and stained with crystal violet. Colonies with more than 50 cells were counted. Clonogenic survival for Clonogenic data was obtained for all cell lines tested in screen.
- Plasmids
- All genes were cloned in pQCXIP plasmid (Clontech, Palo Alto, Calif.). Stable knock-downs were generated with pLKO.1 plasmid (Sigma-Aldrich, St Louis, Mo.; see Khodarev et, al., STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One. 2009 June 8; 4(6):e5821)
- Transfections
- Forty percent (40%) confluent cells were transfected 0.1-1 μg of plasmids using Oligofectamine (Invitrogen, Carlsbad, Calif., USA) or Fugene (Roche) as we previously described (Khodarev et. al., Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2010 February 11; 29(6):920-9). Transfection efficiency was optimized and estimated to be between 10% and 90% depending on the cell type.
- Transcription Assays Real-Time PCR Analysis
- cDNA was synthesized as described previously (see, Khodarev N N, Yu J, Nodzenski E, et al. Method of RNA purification from endothelial cells for DNA array experiments. Biotechniques2002; 32: 316-20). For the internal control, GAPDH was used. PCR was done for 40 cycles at 95° C. for 15 s and 60° C. for 1 min after initial incubations at 50° C. for 2 min and 95° C. for 10 min using SYBR Green PCR reagent in
ABI 7700 System (Applied Biosystems). ΔCt values were calculated according to the manufacturer's instructions. Fold induction/suppression relative to GAPDH was calculated as 2Δct. Fold induction of gene Xsi in gene-specific siRNA transfected cell line relative to gene Xnt in the same cell line transfected by non-targeting siRNA was calculated as 2−(ΔΔCtX), where ΔCt values of all control replicates were averaged. Number of replicates per each group varied from three to six in different experiments. - Cell Extraction, Immunoprecipitation and Western Blotting
- Total cellular protein was extracted in radioimmunoprecipitation assay buffer with protease inhibitors added (1×PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L Na3VO4, 2 μg/mL aprotinin, 1 mmol/L phenylmethylsulfonyl fluoride). All samples were normalized by protein concentration using Bradford reagent and standard solution of bovine serum albumin (1 mg/mL). Concentration of all samples was adjusted to 1 mg/mL and equal amount of protein was loaded in each well. For total proteins, 10 μg of protein was loaded per well. Proteins were separated on 7.5%-12% SDS-PAGE (depending on molecular mass of protein) and transferred to polyvinylidene difluoride membranes (PVDF). Total proteins were detected using the rabbit or goat primary Abs. For loading control, the antibodies for actin (I-19) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; FL-335) were used. All antibodies were purchased from Santa Cruz Biotechnology. Images were quantified with ImageJ software by integration pixel values across the area of specific bands.
- Antibodies
- Western Blots were probed using antibodies at 1:1000 unless stated otherwise. All antibodies were purchased from Santa Cruz Biotechnology.
- Determine JAK/STAT Pathway Survival Mechanisms Specific to Prostate Cancer
- In Vivo Radiotherapy of Prostate Cancer Cells Leads to Upregulation of JAK/STAT Pathways.
- To determine whether the observations regarding upregulation of the JAK/STAT pathway following radiotherapy previously identified in other malignancies are also relevant in prostate cancer, we performed gene profiling experiments using Affymetrix microarrays on PC3 prostate cancer mouse xenografts prior to and following irradiation. Methods of xenograft experiments and DNA array analysis were described by us in detail previously (Kimchi E T et. al, Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005 April 15; 65(8):3146-54.; Khodarev N N et al., Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. 2007 October 1; 67(19):9214-20.). Differential gene expression analysis was performed using standard SAM analysis with a false discovery rate of 5%.
- This gene set was subsequently analysed using Ingenuity Pathway Analysis software, which highlighted the importance of the JAK/STAT signalling in the radiation response of prostate cancer. Based on the analyses of activated down-stream genes one of the potential up-stream regulator is IL6 and IFN-gamma, which through activation of JAK kinases involve STAT3, STAT2 and IRF1/IRF8 genes. Another important node is STAT1/STAT2 activation being linked to the greatest number of differentially up-regulated genes following radiotherapy (
FIG. 1 ). - The aforementioned data suggest that STAT1, STAT2 and/or STAT3 are most relevant to advanced prostate cancer. To determine the potential therapeutic value of targeting the JAK/STAT pathway in prostate cancer, the cells were exposed to the specific JAK2 inhibitor SAR302503. Since it is expected that the greatest value of inhibiting the JAK/STAT pathway is in combination with other toxic insults we evaluated the effect of ionizing radiation used in the treatment of CRPC, and SAR302503 in the genetically related CWR lines (
FIG. 2 ). Cells were plated in p60 dishes with or w/o 0.5 μM of SAR302503 and irradiated with 2 or 5 Gy (or left un-irradiated). Colonies counting and estimation of survival fractions were performed as described elsewhere (Khodarev et. al., 2007, Cancer Research). We found that CWR-R1 is more resistant to IR compared to CWR-22RV1 and cytotoxic activity of IR is not enhanced by the JAK2 specific inhibitor SAR302503. However, effects of IR were significantly enhanced in CWR-22RV1 cell line (seeFIG. 2 ). Therefore these data indicated that SAR302503 can potentiate cytotoxic effects of IR in prostate cancer cells. To extend these observations in preclinical animal models we established xenografts of CWR-R1 and CWR-22RV1. For thispurpose 107 cells were injected in the right flank of each nude mice (5 animals per group) and when tumors reached 200 mm3 in volume mice were either left un-treated, or treated with SAR302503 (120 mg/kg, once a day, 4 days) or irradiated locally (2×10 Gy) or subjected to combined treatments with SAR302503 and IR. As is shown inFIG. 3 combined treatment of CWR-22RV1 tumors with SAR302503 and IR led to the significant suppression of tumor growth by day 9 after beginning of treatment. At the same tumors treatment by SAR302503 alone led to the 4-days growth delay compared with control tumors. These effects were not observed in CWRR1. Molecular differencies between two tumors are currently under investigation. The difference between CWR-R1 and CWR-22RV1 is especially noteworthy since they are isogenic, castrate resistant, and carry both native and splice variant androgen receptor, which is reminiscent of the findings in human prostate cancer specimens. - MCL1 is a Significant Downstream Mediator of the JAK/STAT Survival Pathway in Prostate Cancer Cells
- To better understand the relevant partners of the JAK/STAT survival pathway specifically in prostate cancer, CWR-R1 and CWR-22RV1 cells were tested with gamma radiation after transfection with a panel of 86 siRNA's to previously reported members of the JAK/STAT signaling pathway. The final screen was conducted as follows: On day 1, Lipofectamine RNAiMAX 0.075 μL/well diluted in Opti-MEM (Life Technologies) was added using a Tecan Freedom EVO 200 robotic liquid handling station to previously prepared 384-well microplates (Corning/3712) containing immobilized pooled siRNAs (Dharmacon siGENOME) plated in triplicate for each target gene. Cells were then added using a Thermo Electron MultiDrop Combi dispenser at 500 cells/well in 50 μL of RPMI 1640 media supplemented with 10% FCS. The final siRNA concentration in each well was 50 nM. Plates were be incubated overnight at 37° C., and on
day 2 were treated with ionizing radiation at a dose of either 3 Gy or left untreated. Plates were incubated at 37° C. and then assayed for viability ondays - The siRNA potentiating cytotoxicity to the greatest degree inhibited the anti-apoptotic BCL2 family member MCL1 (see
FIG. 4 .). The below table, Table No. 1, lists the genes presented inFIG. 4 (FIGS. 4A and 4B ). This is different than in cell lines derived from other malignancies for which MCL1 is not one of the top 10 genes selected. As noted above, MCL1 is recognized as one of the most common oncogenes amplified in various cancers, including prostate cancer (Beroukhim R, Mermel C H, Porter D, et al: The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905, 2010). This suggests that the JAK/STAT→MCL1 pathway is uniquely important to prostate cancer, and MCL1 may be an additional therapeutic target. In addition to that apical suppressor of RNA-dependent IFN beta production DHX58 (LGP2), IFN-dependent isopeptidase USP18 and proteosome subunits PSMB8 and PSMB10 were among genes which suppression significantly suppressed viability of prostate cancer cell lines. _These genes can also be used as additional down-stream targets but besides their expression can be associated with sensitivity of the individual prostate tumors to SAR302503. -
TABLE 1 List of genes presented in FIG. 4 (presented as FIGS. 4A and 4B) FIG. 4A FIG. 4B CW22Rv1 + IR CWRR1 + IR MCL1 MCL1 LGALS3BP IRF9 RNF213 USP18 PLSCR1 LGALS3BP DDX60L OASL OASL HERC5 IFITM3 CXCL9 IFIH1 PSMB10 CXCL1 DDX60 WARS ISG15 DDX60 PLSCR1 IFITM1 TRIM21 SAMHD1 SP110 DHX58 TAP1 CXCL9 IFIH1 USP18 B2M DTX3L IFITM3 TRIM21 DTX3L PSMB10 DHX58 EPSTI1 VAMP5 SP110 GBP1 PRIC285 CCL2 IRF9 HERC6 IFI27 TPD52L1 PARP12 WARS IFIT2 EPSTI1 PSMB8 IFITM1 HERC6 IFITM2 BST2 IFI27 MGP TAGLN HNMT CXCL1 SRGN PARP12 TAP1 IFIT3 CXCL10 IGFBP3 TPD52L1 PRIC285 IFI35 IFI44L XAF1 IFI35 OAS1 HNMT DAZ1 ABCC3 IFI16 SRGN THBS1 RTP4 CMPK2 LY96 IFI44 SAMHD1 HERC5 OAS1 CTSS TIMP3 MARCKS XAF1 B2M RNF213 LY96 BST2 CCL5 TNFSF10 MX1 LTK IFI6 MGP EIF2AK2 DAZ1 TRIM14 IFIT2 IFIT1 PSMB8 IRF7 STAT1 DDX58 PSMB9 TIMP3 SAMD9L LTK DDX60L CCL2 IFI44 TNFSF10 IFIT1 LAMP3 MX1 IFIT3 CXCL10 IGFBP3 MX2 STAT1 MARCKS CD74 OAS3 VAMP5 RSAD2 PSMB9 UBA7 NLRC5 DDX58 MX2 IRF7 OAS3 UBE2L6 CCNA1 CTSS GBP1 NLRC5 SAMD9 EIF2AK2 IFITM2 IFI16 RTP4 TRIM14 SAMD9L OAS2 UBA7 LAMP3 UBE2L6 CCNA1 IFI44L CCL5 ABCC3 CD74 ISG15 GBP2 IRF1 THBS1 RSAD2 IFI6 TAGLN CMPK2 LY6E SAMD9 NMI CXCL3 CXCL3 NMI GBP2 IRF1 OAS2 LY6E - The invention has been described in an illustrative manner and it is to be understood the terminology used is intended to be in the nature of description rather than of limitation. All patents and other references cited herein are incorporated herein by reference in their entirety. It is also understood that many modifications, equivalents, and variations of the present disclosure are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced other than as specifically described.
Claims (5)
1. A method of treating a subject with a chemoresistant or radioresistant prostate cancer, the method comprises:
administering a therapeutically effective amount of a selective inhibitor of a JAK/STAT pathway to the subject.
2. The method of claim 1 , wherein the selective inhibitor of the JAK/STAT pathway inhibits at least one of a JAK1, a JAK2, a STAT1 or a STAT3.
3. The method of claim 1 , wherein the prostate cancer has an amplified level of MCL1, DHX58, PSMB8, PSMB9, or PSMB10 expression as compared to a normal control cell.
4. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of at least one of an antineoplastic agent or a radio therapy.
5. The method of claim 4 , wherein the radio therapy comprises at least one of brachytherapy, external beam radiation therapy, or radiation from cesium, iridium, iodine, or cobalt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/901,929 US20160367627A1 (en) | 2013-07-02 | 2014-06-24 | Anti-tumor therapy |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361842045P | 2013-07-02 | 2013-07-02 | |
PCT/US2014/043775 WO2015002766A1 (en) | 2013-07-02 | 2014-06-24 | Anti-tumor therapy |
US14/901,929 US20160367627A1 (en) | 2013-07-02 | 2014-06-24 | Anti-tumor therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/043775 A-371-Of-International WO2015002766A1 (en) | 2013-07-02 | 2014-06-24 | Anti-tumor therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/975,396 Continuation US10561708B2 (en) | 2013-07-02 | 2018-05-09 | Anti-tumor therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160367627A1 true US20160367627A1 (en) | 2016-12-22 |
Family
ID=52144116
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/901,929 Abandoned US20160367627A1 (en) | 2013-07-02 | 2014-06-24 | Anti-tumor therapy |
US15/975,396 Active 2034-06-26 US10561708B2 (en) | 2013-07-02 | 2018-05-09 | Anti-tumor therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/975,396 Active 2034-06-26 US10561708B2 (en) | 2013-07-02 | 2018-05-09 | Anti-tumor therapy |
Country Status (2)
Country | Link |
---|---|
US (2) | US20160367627A1 (en) |
WO (1) | WO2015002766A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11560412B2 (en) * | 2016-04-01 | 2023-01-24 | University Of Maryland, Baltimore | Compositions comprising GRIM-19 therapeutics and methods of use |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021021885A1 (en) * | 2019-07-29 | 2021-02-04 | The Medical College Of Wisconsin, Inc. | Methods of treating advanced prostate cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101170655B1 (en) * | 2003-12-11 | 2012-08-03 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | Compounds for treatment of cell proliferative diseases |
EP1748772A2 (en) * | 2004-04-09 | 2007-02-07 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
RU2456265C2 (en) * | 2006-03-31 | 2012-07-20 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Caffeic acid biologically available for oral use, associated with antitumour medicinal agents |
US20130129675A1 (en) * | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
CN103703174B (en) * | 2011-05-04 | 2017-05-10 | 因特利凯有限责任公司 | Combination pharmaceutical compositions and uses thereof |
-
2014
- 2014-06-24 US US14/901,929 patent/US20160367627A1/en not_active Abandoned
- 2014-06-24 WO PCT/US2014/043775 patent/WO2015002766A1/en active Application Filing
-
2018
- 2018-05-09 US US15/975,396 patent/US10561708B2/en active Active
Non-Patent Citations (1)
Title |
---|
Bolla et al., Combined hormone therapy and radiation therapy for locally advanced prostate cancer, 2012, Critical Reviews in Oncology/Hematology, 84, e30-e34 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11560412B2 (en) * | 2016-04-01 | 2023-01-24 | University Of Maryland, Baltimore | Compositions comprising GRIM-19 therapeutics and methods of use |
Also Published As
Publication number | Publication date |
---|---|
WO2015002766A1 (en) | 2015-01-08 |
US10561708B2 (en) | 2020-02-18 |
US20180256678A1 (en) | 2018-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10421971B2 (en) | Anti-tumor therapy | |
US20190071679A1 (en) | Anti-tumor therapy | |
TWI794171B (en) | Combination therapies of hdac inhibitors and pd-l1 inhibitors | |
US9717731B2 (en) | TEC family kinase inhibitor adjuvant therapy | |
CN110382483A (en) | Condensed N- heterocyclic compound and its application method | |
CN110382482A (en) | Condensed miscellaneous-Heterobicyclic compounds and its application method | |
US20200290978A1 (en) | Compositions and methods for treating cancer | |
KR20160066554A (en) | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy | |
TW200924739A (en) | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents | |
JP2005512961A5 (en) | ||
KR20140022750A (en) | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol | |
US10561708B2 (en) | Anti-tumor therapy | |
US20190134034A1 (en) | Method of Treating Liver Cancer | |
US20140294856A1 (en) | Combination treatment comprising a hdac6 inhibitor and an akt inhibitor | |
KR20190025733A (en) | Method and Pharmaceutical Composition for Treatment of Primary Hormone Resistant Endometrial and Breast Cancers | |
WO2020047487A1 (en) | Methods for treating cancer with rorgamma inhibitors and statins | |
WO2014193964A2 (en) | Prognostic and predictive breast cancer signature | |
TW201306833A (en) | Combination comprising a derivative of the family of the combretastatins and cetuximab | |
JP2007230958A (en) | Enhancer of radiosensitization ability in hypoxic cell radiosensitizer | |
Sood et al. | c19) United States c12) Patent Application Publication | |
Fu et al. | c12) United States Patent | |
Fu et al. | c19) United States c12) Patent Application Publication | |
Abu-Gheida et al. | Radiobiology of Stereotactic Radiosurgery | |
US20210205299A1 (en) | Prodrugs and medical uses thereof | |
Woloschak | 2019 ASTRO RADIATION AND CANCER BIOLOGY STUDY GUIDE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE UNIVERSITY OF CHICAGO, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEICHSELBAUM, RALPH;ROIZMAN, BERNARD;KHODAREV, NIKOLAI;AND OTHERS;SIGNING DATES FROM 20151117 TO 20151207;REEL/FRAME:037382/0152 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |